University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

1-1-2014

Intranasal delivery of therapeutics targeted to CSF and Brain
Prashanth Manda
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Manda, Prashanth, "Intranasal delivery of therapeutics targeted to CSF and Brain" (2014). Electronic
Theses and Dissertations. 1462.
https://egrove.olemiss.edu/etd/1462

This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more
information, please contact egrove@olemiss.edu.

INTRANASAL DELIVERY OF THERAPEUTICS TARGETED
TO CSF AND BRAIN

A Dissertation
presented in partial fulfillment of requirements
for the degree of Doctor of Philosophy
in the Department of Pharmaceutics and Drug Delivery
The University of Mississippi

by
PRASHANTH MANDA
December 2014

Copyright © 2014 by PRASHANTH MANDA
All rights reserved

ABSTRACT

Blood-brain barrier and blood-cerebrospinal fluid barrier limit the systemic delivery of
therapeutics to the brain and cerebrospinal fluid (CSF) respectively. Therapeutic agents targeting
CNS are currently being administered by invasive routes which are not patient compliant and do
not allow frequent administration. Intranasal delivery of therapeutics to target CSF and brain is a
noninvasive route of administration which is patient compliant and allows frequent
administration.
In the current study, the plausibility of delivering ziconotide and cefotaxime to CSF and
brain respectively via intranasal pathway using barrier modulating agents like chitosan was
investigated. The ability of chitosan to enhance the permeation of therapeutic agents was
investigated across bovine olfactory mucosa and the pharmacokinetics of therapeutic agents
administered via intranasal route was investigated in Sprague dawley rats.
Overall, it was found that intranasal delivery of therapeutic agents to brain and CSF was
significantly enhanced when chitosan was used as a barrier modulating agent. However, the
elimination of therapeutic agents was rapid from the Brain/CSF. Therefore to prolong the drug
levels in the target tissue fluids, thermosensitive in situ gels were developed using poloxamers.
As the poloxamers are poorly cleared from the applied region particularly when multiple
applications are executed subsequently, the us of multiblock copolymer which degrades at
mucosal pH was explored as an alternative as well. The gel formulations prolonged the brain
ii

levels of cefotaxime as well as CSF levels of ziconotide as well.
This project has clearly demonstrated that intranasal administration could be used to
administer therapeutic agents of interest to target brain or CSF. The bioavailability could be
improved using barrier modulating agents and in situ gel formulations.

ii

DEDICATION

Dedicated to my Mother (Sadalaxmi Manda), Father (Sarangapani Manda),
Wife (Manasa Cidda) and Potti (Praneeth Manda).

ii

ACKNOWLEDGEMENTS

I would like to express my deep and sincere gratitude to my advisor, Dr. S. Narasimha
Murthy for his support, patience and encouragement throughout my research work. His
motivation and support at all the time during my research helped me learn many aspects required
to achieve high standards in research. I am ever grateful for all his kind support.
I would like to take this opportunity to express my sincere thanks to Dr. Michael A.
Repka, Dr. Seongbong Jo, Dr. Dhammika Nanayakkara for accepting my request, spending their
valuable time and providing valuable suggestions during my prospectus that I believe have
improved my overall work. It was kind of Ms. Debbie P. King for helping me with all the
departmental procedures and providing all the supplies required on time.
I owe a great thanks to my senior lab members (Dr. Siva Ram Kiran Vaka and Dr.
Srinivasa Murthy Sammeta) for teaching me the research basics of our lab. I was lucky enough
to work with Abhishek Juluri and would like to thank him for all his help and support. I also
thank all the present group members (Avadhesh, Abhijeeth, Naresh and Murali) and all the
graduate students of pharmaceutics and drug delivery department for their support in various
projects.

iii

I would like to acknowledge the help of Dr. Quintin R. Smith, Dr. Ramakrishna Samala
(Department of Pharmaceutical Sciences, Texas A&M University, Amarillo, TX), Dr.Santanu
Kundu (Department of Chemical Engineering, Mississippi State University) and Scott Rone
(Department of Health and safety) for their assistance in carrying out the ziconotide project.
I owe my loving thanks to my mother (Sadalaxmi Manda), father (Sarangapani Manda)
and wife (Manasa Cidda) for allowing me to study at University of Mississippi and providing me
with all the support and encouragement. My special gratitude to my brother (Praneeth Manda)
for his loving support.
I sincerely acknowledge the funding sources that made my Ph.D work possible.

iv

TABLE OF CONTENTS

ABSTRACT ................................................................................................................................... ii
DEDICATION............................................................................................................................... ii
ACKNOWLEDGEMENTS ........................................................................................................ iii
LIST OF FIGURES .................................................................................................................... vii
LIST OF TABLES ....................................................................................................................... xi
PART1. INTRANASAL DELIVERY OF ZICONOTIDE TO CEREBROSPINAL FLUID 1
1. INTRODUCTION ................................................................................................................. 2
2. CHRONIC PAIN MANAGEMENT .................................................................................. 11
3. ZICONOTIDE ..................................................................................................................... 13
4. NOSE TO CSF DELIVERY OF ZICONOTIDE ............................................................. 17
5. IN SITU GEL FORMING INTRANASAL FORMULATIONS ..................................... 34
6. POLOXAMER ..................................................................................................................... 35
7. FORMULATION AND EVALUATION OF IN SITU INTRANASAL GELS FOR
DELIVERY OF ZICONOTIDE TO CSF ............................................................................. 37
Part II. INTRANASL DELIVERY OF CEFOTAXIME TO BRAIN ................................... 51
8. CEFOTAXIME.................................................................................................................... 52
9. FORMULATION AND EVALUATION OF CEFOTAXIME IN SITU INTRANASAL
GELS ........................................................................................................................................ 54
v

10. BIODEGRADABLE MULTIBLOCK COPOLYMER FOR IN SITU GEL
FORMULATION .................................................................................................................... 67
11. FORMULATION AND EVALUATION OF MULTI BLOCK COPOLYMER IN
SITU INTRANASAL GELS ................................................................................................... 68
BIBLIOGRAPHY ....................................................................................................................... 80
VITA............................................................................................................................................. 93

vi

LIST OF FIGURES

Figure 1. Channels created by olfactory ensheathing cells to access CSF and olfactory bulb.
[Modified from Dhuria, S.V. et al., J. Pharm. Sci., 99, 4,2010.].................................................. 3
Figure 2. Schematic representation of drug transport from Nose to CNS. ................................. 4
Figure 3. Fate of drugs exposed to olfactory and respiratory region. [Modified from Dhuria,
S.V. et al., J. Pharm. Sci., 99, 4,2010.]. ......................................................................................... 5
Figure 4. Drug transport from nasal mucosa to brain entry sites. [Modified from Lochhead JJ
et al., Adv.Drug Deliv. Rev., 64,7, 2012.]. ..................................................................................... 6
Figure 5. Drug transport from CSF to interstitial fluid and perivascular spaces. [Modified
from Dhuria, S.V. et al., J. Pharm. Sci., 99, 4,2010.]. .................................................................. 7
Figure 6. Structure of Ziconotide ................................................................................................ 14
Figure 7. Mechanism of action of ziconotide [Modified from Schmidtko A et al., Ziconotide
for treatment of severe chronic pain, The Lancet., 375, 9725,2010.]. ....................................... 15
Figure 8. Schematic representation of the experimental plan. ................................................. 18
Figure 9. Chromatogram representing 125I and 125I ziconotide. ................................................ 25
Figure 10. Negative mode ESI-MS spectra of free Iodine acquired on a Waters synapt HDMS.
....................................................................................................................................................... 26
Figure 11. Pharmacokinetics of ziconotide in the CSF following intrathecal (●) and
intravenous (▲) administration. ................................................................................................. 28
vii

Figure 12. In vitro permeation of ziconotide across the bovine olfactory mucosa in presence of
control (♦), 0.1% chitosan (■), 0.25% chitosan (▲) and 0.5% chitosan (●). ............................ 29
Figure 13. Pharmacokinetic profile of ziconotide in CSF following intranasal administration
of ziconotide with chitosan (■), without chitosan (♦) and intravenous (▲) administration of
ziconotide. ..................................................................................................................................... 30
Figure 14. Pharmacokinetic profile of ziconotide in plasma following intranasal
administration of ziconotide with chitosan (■), without chitosan (♦) and intravenous (▲)
administration of ziconotide. ....................................................................................................... 33
Figure 15. Experimental plan of ziconotide in situ intranasal gels. .......................................... 38
Figure 16. Determination of gelation temperature, storage and loss modulus of 18% (■,□),
20% (●,○) and 22% (▲,Δ) KP 407.Closed markers represent storage modulus and open
markers represent loss modulus. ................................................................................................. 45
Figure 17. In vitro release studies of ziconotide KP 407 (■) and KP 407 chitosan (♦) gels. .... 47
Figure 18. In vitro permeation studies of ziconotide KP 407 (■), KP 407 chitosan (♦) gels and
ziconotide solution in PBS (●) across bovine olfactory mucosa. ............................................... 47
Figure 19. Pharmacokinetic profile of ziconotide in CSF following intranasal administration
of ziconotide KP 407 without chitosan (■), with chitosan (♦) and ziconotide solution with
chitosan (●). ................................................................................................................................. 48
Figure 20. Pharmacokinetic profile of ziconotide in CSF following intranasal administration
of ziconotide KP 407 without chitosan (■), and with chitosan (♦). ............................................ 49
viii

Figure 21. Pharmacokinetic profile of ziconotide in plasma following intranasal
administration of ziconotide KP 407 without chitosan (■), with chitosan (♦) and ziconotide
solution with chitosan (●). ........................................................................................................... 50
Figure 22. Effect of chitosan 0.1% (♦) and 0.25%(■) over control (●) on in vitro permeation
studies of cefotaxime across bovine olfactory mucosa. .............................................................. 61
Figure 23. In vitro release studies of cefotaxime from CKP (▲), CKP-0.1C (●), CKP-0.25C (♦)
and CKP-0.5C (■). ....................................................................................................................... 61
Figure 24. In vitro permeation studies of CS (●), CS-0.25C (■), CKP (▲) and CKP-0.25C (♦)
gels across bovine olfactory mucosa. .......................................................................................... 62
Figure 25. Pharmacokinetics of cefotaxime in brain following intranasal administration of
CS-0.25C (■), CKP (▲), CKP-0.25C (♦) and intravenous CS (●). ............................................ 63
Figure 26. Pharmacokinetics of cefotaxime in plasma following intranasal administration of
intravenous CS (●). Insert picture shows pharmacokinetics of cefotaxime in plasma following
intranasal administration of CS-0.25C (■), CKP-0.25C (♦), and CKP (▲). ............................ 65
Figure 27. Determination of gelation temperature, storage and loss modulus of 10% (■,□),
15% (▲,Δ) and 20% (♦,◊) MBCP. Closed markers represent storage modulus and open
markers represent loss modulus. ................................................................................................. 73
Figure 28. In vitro release studies of cefotaxime from MBCP (■),and MBCP-0.25C (♦). ....... 76
Figure 29. In vitro permeation studies of CS (▲), CS-0.25C (●), and MBCP-0.25C (■) gels
across bovine olfactory mucosa. .................................................................................................. 77
ix

Figure 30. Pharmacokinetics of cefotaxime in brain following intranasal administration of
CS-0.25C (▲), MBCP (■),MBCP-0.25C (♦) and i.v administration of cefotaxime (●). ........... 78

x

LIST OF TABLES

Table 1. Distribution of rats for pharmacokinetic studies of ziconotide in CSF and plasma
following intranasal, intravenous and intrathecal administration of ziconotide solution. ....... 23
Table 2. PK parameters of ziconotide in CSF following intranasal and intravenous
administration. ............................................................................................................................. 31
Table 3. PK parameters of ziconotide in plasma following intravenous and intranasal
administration. ............................................................................................................................. 33
Table 4. Distribution of rats for pharmacokinetic studies of ziconotide in CSF and plasma
following intranasal administration of in situ forming intranasal formulations...................... 43
Table 5. Gelation temperature, storage modulus and complex viscosity of 18, 20 and 22% KP
407................................................................................................................................................. 44
Table 6. Adhesion properties of KP 407 with and without chitosan. ......................................... 45
Table 7. Gelation temperature, gel strength and complex viscosity of 20% KP 407 with 0.25%
chitosan......................................................................................................................................... 46
Table 8. Gelation temperature, storage modulus and complex viscosity of 10, 15 and 20%
MBCP. .......................................................................................................................................... 74
Table 9. Gelation temperature, gel strength and complex viscosity of 15% MBCP and 15%
MBCP with 0.25% chitosan. ........................................................................................................ 75

xi

PART1. INTRANASAL DELIVERY OF ZICONOTIDE TO CEREBROSPINAL FLUID
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1. INTRODUCTION

Intranasal (IN) route offers a pathway that is independent of various barriers (Blood Brain and
Blood-cerebrospinal fluid (CSF) barrier) for the delivery of drugs to CNS [1-8]. This route offers
advantages like ease of administration, patient compliance, low dose requirement and minimal
side effects [9-15]. The overall objective of the project was to aim intranasal route as a pathway
to deliver a few selected therapeutic agents to the brain and the CSF.
1.1. Nasal Anatomy
Nasal cavity extends from nostrils to the nasopharynx and is bifurcated longitudinally into two
cavities by the nasal septum [16, 17]. The nasal cavity has inferior, middle and superior
turbinates which together have an absorptive surface area of ~160 cm2 (humans), which help in
filtering, humidifying and warming inhaled air [18-20]. Different epithelia like squamous,
respiratory, transitional and olfactory epithelia are present in the nasal cavity [21-23]. The
respiratory epithelium which covers major part of the dorsal and ventral nasal cavities is highly
vascularized and is responsible for drug absorption. The olfactory regions embrace ~10% of the
nasal epithelium and play a major role in transport of drugs to the brain and cerebrospinal fluid
[13, 24-28].
The olfactory region consists of pseudostratified columnar epithelium and is located in the
posterior part of the nasal cavity which aids in perception of odor. Olfactory sensory neurons
(OSN) possess non motile cilia which open to the external environment [29]. Axons of one OSN
2

converge with each other and result in formation of nerve bundles termed as fila olfactoria.
Olfactoria are enclosed by olfactory ensheathing cells which are further enclosed by olfactory
nerve fibroblasts [30-32]. The olfactory nerve which travels through the cribriform plate into the
brain is a part of the olfactoria and usually terminates on the dendrites of the mitral,
periglomerular and tufted cells in glomeruli of the olfactory bulb [33-37].

Figure 1. Channels created by olfactory ensheathing cells to access CSF and olfactory bulb.
[Modified from Dhuria, S.V. et al., J. Pharm. Sci., 99, 4,2010.].
Nasal respiratory epithelium is a pseudostratified columnar secretory epithelium comprising of
goblet, ciliated, intermediate and basal cells (Figure 1). The respiratory epithelium is innervated
by branches of the trigeminal nerve which has both sensory and motor root and exits the pons
laterally. The sensory nerves project to trigeminal nuclei located in the brainstem and the spinal
cord where a portion of the trigeminal ganglion cells with its sensory endings in the nasal
3

epithelium connects to the olfactory bulb. The motor nucleus has motor neurons that travel in the
small motor root to the muscles of mastication [29, 38, 39].
1.2. Steps involved in drug transport from the nasal region to the central nervous system
Delivery of drugs following intranasal administration to the CNS region occurs along the
olfactory and trigeminal components [37, 40]. Drugs from these components will be delivered to
the olfactory bulb and the brain stem respectively (Figure 2) [13, 40]. The drugs will be further
disposed to other regions of CNS following three sequential transport steps: i). Transport across
epithelial membrane barriers ii). Transport to brain entry sites from nasal mucosa iii). Transport
from brain entry sites to other sites. The mechanism of drug absorption during its navigation
along the nasal cavity via the olfactory pathway follows transcellular, paracellular or neuronal
transport pathways.

Olfactory

Brain

CSF
Blood

Nose

Organ
tissue

Clearance

Figure 2. Schematic representation of drug transport from Nose to CNS.

4

Elimination

a). Transport from epithelial barrier
Drug transport across the olfactory and respiratory epithelium is predominantly by intracellular
or extracellular pathways (Figure 3). Intracellular pathways across olfactory and respiratory
epithelium include endocytosis into olfactory sensory neuron and peripheral trigeminal nerve
respectively [41-44]. Substances subjected to olfactory endocytosis will subsequently undergo
intraneuronal transport to the olfactory bulb. Whereas, substances subjected to peripheral
trigeminal endocytosis will be transported to the brainstem [45, 46]. Extracellular pathways
across olfactory and respiratory epithelium will be responsible for transport to lamina propria by
paracellular diffusion [47-49].

Figure 3. Fate of drugs exposed to olfactory and respiratory region. [Modified from Dhuria,
S.V. et al., J. Pharm. Sci., 99, 4,2010.].
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b). Transport from nasal mucosa to brain entry sites
Substances may enter the systemic circulation once they cross the nasal epithelium as the nasal
region has a rich supply of nasal blood vessels. Therefore, nasal vasculature may act as a sink
and prevent drugs reaching CNS. Substances that escape absorption into systemic circulation
may drain to the deep cervical lymph nodes through nasal lymphatic vessels in the lamina
propria [50-52].
Substances which cross the nasal epithelium and reach the lamina propria may potentially reach
CNS if they escape both absorption into blood circulation and drainage from nasal lymphatics.
Additional extracellular pathways to reach the brain will be provided by olfactory ensheathing
cells as they maintain continuous open spaces for the regrowth of olfactory nerve fibers [31, 50].
Apart from these, the olfactory and trigeminal nerves (Cranial nerves) may also help in
transporting substances from nasal cavity to the CSF (Figure 4)[53].

Figure 4. Drug transport from nasal mucosa to brain entry sites. [Modified from Lochhead JJ et
al., Adv.Drug Deliv. Rev., 64,7, 2012.].
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c). Transport form brain entry sites to other CNS areas
Drug distribution from olfactory bulb and brainstem to the other areas of the CNS is due to
transfer and uptake of drugs from secondary neurons to peripheral neurons (intracellular) via
convective transport within cerebral perivascular spaces or local diffusion from perivascular
spaces into the parenchyma (extracellular) (Figure 5). Substances like proteins, peptides adopt
convective mechanism along olfactory and trigeminal components in the nasal epithelium to the
olfactory bulb and brain stem.

Figure 5. Drug transport from CSF to interstitial fluid and perivascular spaces. [Modified from
Dhuria, S.V. et al., J. Pharm. Sci., 99, 4,2010.].
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1.3. Roadblocks for intranasal delivery
The absorption of the drugs across the nasal epithelium depends upon physicochemical
properties of the drug. The absorption rate of lipophilic drugs is generally high whereas that of
hydrophilic drugs depends on various factors like molecular weight, membrane permeability,
mucociliary clearance and enzymatic degradation.
Low membrane permeability across nasal mucosa is considered to be a major limiting factor for
the absorption of polar drugs and peptides. Drugs cross the epithelial membrane either by
transcellular or paracellular route, receptor mediated or vesicular transport, or driven by the
concentration gradient [54].
Drugs will be subjected to rapid mucociliary clearance as they are not easily absorbed across the
nasal membrane [55-57]. The mucociliary clearance confines the residence time of the drugs and
triggers the half-life of the intranasal liquid and powder dosage forms to an order of 15-20 min
[58]. The clearance of drugs is also influenced by the site of deposition of the formulation either
in the anterior or posterior area. Drugs targeted to the anterior part of the nasal cavity may be
subjected to minimal nasal clearance and promote absorption compared to the deposition in
further back region.
Enzymatic degradation may also be a potential limiting factor for the poor bioavailability of
drugs delivered across the nasal epithelium [59,60]. Exopeptidases like mono and
diaminopeptidases may cleave the peptides at N and C termini and endopeptidases can attack the
internal peptide bonds [61]. In addition an enzyme barrier may be formed because of the
proteolytic enzymes and other mucosa secretases in the mucosal secretions that act as a rate
limiting step, decrease the delivery amounts and therapeutic effects of peptides and proteins [62].
8

1.4. Formulation strategies to enhance intranasal drug delivery
As mentioned above different protective barriers like nasal mucosal clearance, drug metabolizing
enzymes, tight junction proteins, and nasal vasculature limits bioavailability of drugs to CNS
when administered via intranasal route. One or more of the formulation approaches such as
enhancing the drug permeability across the nasal epithelium, minimizing clearance from the
nasal passage and protecting drugs from degradation would serve as fosters to enhance intranasal
drug delivery to CNS. Parameters like osmolarity, pH, and ionization of the drug can also affect
the permeability of the drugs to the CNS via intranasal delivery.
a). Formulation strategies to alter membrane permeability
Intranasal administration of drugs to the CNS is limited because of the poor permeability of the
mucosal epithelium to drugs. Improving permeability of mucosal epithelium in the olfactory
region could enhance extracellular transport to the CNS along olfactory and trigeminal nerve.
Permeation enhancers like surfactants, tight junction modifiers, bile salts, lipids and polymers
may be used to modify membrane permeability. Tight junctions present in the epithelia also limit
the permeability to a certain extent and limits the bioavailability of the drug molecules. Barrier
modulating agents (BMA) like cationic polymers (chitosan and its derivatives, poly-L-arginine,
poly-L-lysine), bile salts and bile salts derivatives (sodium deoxycholate, sodium glycocholate,
sodium taurodihydrofusidate), fatty acids and fatty acid derivatives (linoleic acid), phospholipids
(lysophosphatidylcholine) and surfactants (sodium lauryl sulfate) when co-administered may
enhance the absorption across the nasal mucosa. These BMA’s may alter the permeability of the
epithelium or influence the tight junctions or work as enzymatic degradation inhibitors and
enhance the permeation.
9

Cell shrinkage or expansion caused due to osmolarity changes of the formulation may enhance
the intercellular or extracellular transport mechanism to the CNS region. A change in the amount
of vasoactive intestinal peptide with a change in osmolarity of the formulation was reported [63].
Ionization state of the drug and pH of the formulation may also affect the permeability of the
drugs when administered intranasally. Sulphonamides with different fractions of ionization when
administered intranasally were found to have differences in permeability to the CSF [64].
b). Formulation strategies to reduce mucociliary clearance
Mucociliary clearance reduces the contact time of drugs with the nasal epithelia and rapidly
removes drugs from the delivery site. Use of mucoadhesive agents, nanoparticles, absorption
enhancers, surfactants, lipid emulsions, vasoconstrictors, and efflux transporter inhibitors are
some of the potential approaches to reduce the clearance and enhance the residence time [65-70].
Mucoadhesive agents like chitosan forms electrostatic interactions with the negatively charged
surface of the epithelial cells and reduces the clearance from the nasal epithelia. It also has the
capability to reversibly open the tight junctions which increase the extracellular ability of drug
along the olfactory and trigeminal nerve pathway into CNS.
Nanoparticle with modified surface properties may be used for mucosal binding, reduce
clearance and enhance delivery to CNS. Ulex europaeus agglutinin I and wheat germ agglutinin
conjugated horseradish peroxidase when conjugated with PEG-PLA nanoparticles increased the
levels of fluorescent markers in different regions of the brain compared to unmodified
nanoparticles. Treatment with an inhibitor of the efflux transporters or reducing the clearance
into the blood using vasoconstrictors was also reported to allow more drugs to the CNS.
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2. CHRONIC PAIN MANAGEMENT

2.1. Significance
Treatment of chronic or recurring pain is a major therapeutic challenge. It has been reported that
more than 15% of the general population experience chronic pain and approximately, 2/3 of
these people have had pain for more than 5 years. It is reported that 1.2 million people in the
United States have sustained traumatic spinal cord injuries. Approximately 11,000 new injuries
occur each year. Many studies have reported that the pain significantly affected the quality of
life of patients, interfered with their participation in daily activities and reduced productivity.
Therefore, there is an urgent need to develop simple and effective methods to treat chronic pain
[71, 72].
2.2. Challenges for pain management
A variety of medications are generally administered via oral, transdermal and parenteral routes
for the treatment of chronic neuropathic pain. Despite the availability of very potent drugs, the
treatment of chronic pain remains challenging [73]. It has been found that systemic
administration of drugs fails to achieve adequate pain relief in up to ~10–30% of patients [71].
The reasons for poor patient response to drugs are attributed mainly to poor bioavailability of
drugs to cerebrospinal fluid (CSF) (due to the physiological barriers protecting the CNS) and
short duration of activity of drugs due to rapid clearance of drug from the CSF. In addition,
serious adverse effects are one of the important issues, which can restrict the use of systemic
11

analgesics. Regional delivery in the form of frequent intrathecal injections or prolonged infusion
using pumps was found to offer prolonged therapeutic effect in most patients [74]. However,
intrathecal administration is invasive; hence traumatic and not patient compliant. The intrathecal
pumps are also reported to be associated with complications such as trauma, infection and even
dose dumping. Therefore, there is an urgent, unmet need to develop an alternative, noninvasive,
patient

compliant

and

effective

method
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of

delivering

drugs

to

CSF.

3. ZICONOTIDE

Ziconotide (ω-conotoxin) is a synthetic peptide equivalent of ω-conopeptide MVIIA isolated
from the Magician’s cone snail, Conus magus. It has a novel mechanism of action that involves
potent and selective blockade of presynaptic neuronal N-type voltage sensitive calcium channels
concentrated in the dorsal horn of the spinal cord. It is prescribed for the management of severe
chronic pain in patients who are intolerant or have poor response to opioids and other analgesic
drugs [75, 76]. However, due to peptide nature of the drug and poor ability to cross the bloodCSF barrier, bioavailability to CSF following systemic administration is poor. Moreover,
systemic administration of ziconotide is also known to effect the function of sympathetic and
parasympathetic nerves and cause profound side effects by blocking many types of calcium
channels [77]. Therefore, recently this non-opioid drug was approved only for intrathecal (IT)
administration by FDA and European Medicines Agency.
3.1. Chemical Structure
Ziconotide is a 25 amino acid sequence with amidated carboxyl terminus and cysteines at both
the N and C-terminal which are covalently linked to two other cysteines internally via disulfide
bridges. The disulfide bonds linked in the disulfide bridge pattern are responsible for the
pharmacological activity of the peptide.
Apart from the disulfide bonds a triple standard beta sheet enhances the structural stability,
binding potency, selectivity and improves the resistance against the peptidases.
13

Figure 6. Structure of Ziconotide
3.2. Mechanism of Action
Ziconotide possess a high binding affinity for N-type voltage-sensitive calcium channels. The
loops located between cysteine-8 and cysteine-15 amino acids are responsible for the selectivity
whereas the tyrosine-13 is responsible for the binding efficiency towards N-type channels. Ntype channels are localized at the presynaptic terminals and are expressed at high density on the
central terminals of primary afferent neurons which terminate in the dorsal horn of the spinal
cord. These channels allow the calcium influx which is required for the release of
neurotransmitters. In case of a nociception the excitatory transmitters such as glutamate and
neuropeptides will be released into the dorsal horn which in turn stimulates neurons in the spinal
cord and transmits the nociception to supraspinal brain areas. Ziconotide when bound to the N-
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type calcium channel blocks the release of the neurotransmitters from the primary afferent nerve
terminals to the synaptic cleft (Figure 7).

Figure 7. Mechanism of action of ziconotide [Modified from Schmidtko A et al., Ziconotide for
treatment of severe chronic pain, The Lancet., 375, 9725,2010.].
3.3 Intrathecal administration of ziconotide
Although, intrathecal administration of ziconotide is considered to be an effective route to target
the spinal cord region, the procedural and device complications may be a major concern when
delivering drugs via intrathecal route. Meningitis may be a potential complication which might
be caused because of the contamination of the micro infusion device, infected pump pocket, or
catheter tract. About 93% of the population (38 out of 41) using external infusion devices for
administration of ziconotide were prone to meningitis in the clinical studies conducted by Jazz
Pharmaceuticals. It is also reported in FDA safety watch report that, 3% of the subjects (40
patients out of 1254) were prone to meningitis using an internal micro-infusion devices [78].
Complications like pump failure, program error, and incorrect refill may lead to overdosage of
15

ziconotide which might lead to exaggerated pharmacological effects like ataxia, spinal
myoclonus or nystagmus. Failure in adopting proper titrations of ziconotide may also lead to
cognitive and neuropsychiatric side effects.
Neurological deficits can be developed because of the procedure failure and inflammatory mass
development catheter tip. Therefore, considering all the complications associated with the
existing therapy for intrathecal administration of ziconotide, there is an urgent need to develop
simple

and

effective

methods
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to

treat

chronic

pain.

4. NOSE TO CSF DELIVERY OF ZICONOTIDE

Intranasal delivery is a noninvasive route that offers a direct pathway from nose to CSF via the
olfactory apparatus [79-84]. Nose to CSF pathway could deliver drugs directly to the CSF
bypassing the blood-CSF barrier. In addition, intranasal delivery would be patient compliant and
allows frequent administration. Apart from this, treatment with nasal formulations would be less
expensive than intrathecal therapy. Nasal formulations can be self-administered and do not
require physician supervision during administration unlike in case of intrathecal or parenteral
formulations [85]. Therefore, in this project the plausibility of delivering ziconotide to the CSF
via intranasal route was investigated.
4.1. Objectives of the project
Experiment 1: To investigate the effect of chitosan on the permeation of drugs across the
olfactory mucosa.
Rationale: The permeation of ziconotide across the olfactory mucosa was investigated in
presence and absence of chitosan. Kandimalla and coworkers [86] and Schmidt and coworkers
[87] has reported bovine olfactory mucosa to be a closer model to human olfactory mucosa due
to the similarity in trans-epithelial electrical resistance and metabolic enzyme profiles. The drug
transport and metabolic pathways of bovine olfactory mucosa are similar to human olfactory
mucosa [87]. Required preliminary idea about the transport mechanism, extent of transport
enhancement and the critical concentration of ingredients was obtained from transport studies.
17

Transepithelial electrical resistance (TEER) has been shown to reflect the permeability status of
the biological barriers [88].
Experiment 2: To investigate the pharmacokinetics of ziconotide in the CSF following
intranasal administration.
Rationale: Estimating the concentration of ziconotide in the CSF is more relevant to predict
therapeutic effectiveness and toxicity of the drug, as the site of drug action is in the dorsal horn
of the spinal cord. Thus, CSF collected from the cisternae magna was used to investigate the
kinetics of ziconotide.

Figure 8. Schematic representation of the experimental plan.
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4.2. MATERIALS AND METHODS
4.2.1. Chemicals
Ziconotide acetate, chitosan (MW ~250 kDa, 75-80% deacetylation), Krebs-ringer bicarbonate
buffer (KRB) (premixed powder), acetone, hydrochloric acid were procured from Sigma
chemicals (St. Louis, MO, USA). Ziconotide acetate was radio labeled by PerkinElmer
(Waltham, MA) using 125I. Sodium perchlorate, methanol, trifluoroacetic acid and acetonitrile
were obtained from Fisher Scientific (Atlanta, GA, USA).
4.2.2. Preparation of Olfactory mucosa
In vitro permeation studies were carried out using bovine olfactory mucosa obtained from PelFreez Biologicals (Rogers, AR, USA). Freshly excised frozen tissue was obtained from the
supplier and used within 24 h of excision. The tissue was thawed in KRB for a period of 30 min
before carrying out the permeation studies.
4.2.3. Analytical Method
a). Quantification of unlabeled neat ziconotide
The HPLC system (Waters, 1525) consisting of a Phenomenex C-18 analytical column (4.6 mm
X 150 mm, Luna 5.0 µ) and a variable wavelength detector (Waters, 2487) were used for
Quantification of ziconotide. The mobile phase was made up of a gradient elution starting with
100% mobile phase A for 2 minutes, shifting to 70% mobile phase A:30% mobile phase B over
12 minutes, then to 30% mobile phase A:70% mobile phase B for next 10 min, and to 100%
mobile phase A for approximately 6 minutes to re-equilibrate the column. The flow rate was 1.0
mL/min and the column effluent was monitored at 212 nm. Mobile phase A consisted of 98% 25
mmol/L sodium perchlorate, 2% methanol, and 0.05% trifluoroacetic acid; mobile phase B
19

consisted of 49.95% acetonitrile, 49.95% water, and 0.1% trifluoroacetic acid.
b). Estimation of 125I ziconotide
The samples were quantitated using both HPLC and gamma counter. Samples were injected onto
a HPLC column using the same conditions mentioned above. The fractions eluted from the
column were collected at regular intervals to separate free iodine from the iodine that is bound to
the peptide. The fractions collected every minute were quantitated for radioactivity using a
Beckman Gamma counter (Pasadena, CA) [89].
4.2.4. Stability of ziconotide
a). Stability of ziconotide in tissue homogenate
Bovine olfactory mucosa was homogenized in a glass vial using a high shear tissue homogenizer
(Fisher Tissuemizer®) in KRB. To this, known concentration of ziconotide was spiked and
incubated at 340C for 6 h. Samples were collected at regular intervals, filtered and analyzed
using HPLC.
b). Stability of ziconotide in CSF
CSF was collected from the cisternae magnae of the Sprague dawley rats. The CSF was spiked
with a known concentration of ziconotide. The drug with CSF was incubated at 370C for a period
of 6 h and samples were collected intermittently at regular intervals. The collected samples were
analyzed using HPLC.
4.2.5. Preparation of chitosan and 125I ziconotide solution
The chitosan solution was prepared by dissolving the required quantity of chitosan in a fraction
of 1% glacial acetic acid solution prepared in KRB (pH 5.5). The second fraction of the KRB
was used to dissolve both the cold ziconotide and
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I ziconotide. The ziconotide and chitosan

solutions were mixed by vortexing. The solutions prepared without incorporation of chitosan
served as control.
4.2.6. Experiment for In vitro permeation studies
In vitro permeation studies were carried out using vertical Franz diffusion apparatus (Logan
Instruments, Somerset, NJ). The olfactory mucosa was sandwiched between the donor and
receiver compartment such that the dorsal side of the tissue is facing the donor compartment and
the ventral side facing the receiver compartment. Ag/AgCl electrodes (procured from Alfa Aesar,
Ward Hill, MA) in the form of circular ring with a diameter of 0.5 mm were placed in the donor
and receiver compartment and were 2 mm away from the tissue in both compartments. A load
resistor RL (100 kΩ) was placed in series with olfactory mucosa after filling the donor and
receiver compartments with 500 µL and 5 mL of KRB respectively. The voltage drop across the
whole circuit (Vo) and across the mucosa (VE) was measured using a waveform generator and
multimeter (Agilent Technologies, Santa Clara, CA). The resistance in kΩ cm2 was measured by
applying a small voltage of about 100 mv at 10 Hz [90].
RE =

VERL
VO-VE

Where RE is the olfactory mucosa resistance and RL is the load resistor in kΩ.
4.2.7. Effect of chitosan on the permeation of ziconotide
The effect of different concentrations of chitosan (0.1%, 0.25% and 0.5% w/v) on the permeation
of ziconotide was investigated. Drug-chitosan solution was prepared by dissolving the required
quantity of chitosan in 1% glacial acetic acid solution in KRB followed by addition of ziconotide
(250 µg/mL). Drug solution with chitosan (100 µL) was placed in the donor compartment and
21

KRB was filled in the receiver compartment. Control set of experiments were run without
incorporation of chitosan in donor solution. The receiver compartment buffer was sampled at
different time points, injected on to the HPLC to separate the free Iodine and the fractions were
measured for 125I ziconotide using a Beckman gamma counter.
4.2.8. Extraction of ziconotide from plasma
Blank plasma obtained from untreated rats was spiked with known concentrations of ziconotide
and calibration curve was plotted using the analytical method as mentioned above.
The rat plasma samples containing ziconotide were extracted initially by vortexing 100 µL of
plasma with 0.9 ml of Acid acetone (Acetone:Water:HCl ; 40:6:1). Proteins were then removed
by centrifugation at 40C for 15 min. The supernatant was injected onto the HPLC for fraction
separation and was quantitated using gamma counter [91].
4.2.9. Pharmacokinetic studies
Pharmacokinetic studies were carried out in Sprague dawley rats (male, 250-300 g; Harlan
Company, Indianapolis, IN, USA). The experimental procedures were approved by the
Institutional animal care and use committee (IACUC) at the University of Mississippi (Protocol
# 12-007 & 13-015). The rats were categorized into four groups. Each group was subdivided into
seven groups (15, 30, 60, 120, 180, 240, 360 min) with each subgroup having 3 rats. The rats
were anesthetized using ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p injection).
Ziconotide solution with and without 0.25% w/v chitosan (100 µg/kg) was administered by
intranasal route (i.e. administration of drug directly into the posterior segment of the nose using a
microsyringe connected with a soft polymer capillary) to rats in groups I and II respectively.
Whereas, ziconotide was administered by i.v route for rats belonging to group III (Table 1).
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Intrathecally catheterized rats (Group IV) were obtained from Charles River (Charles River,
Wilmington MA). Ziconotide solution (100 µg/kg) was administered to carry out the
pharmacokinetic studies of ziconotide in CSF and plasma following intrathecal administration.
Table 1. Distribution of rats for pharmacokinetic studies of ziconotide in CSF and plasma
following intranasal, intravenous and intrathecal administration of ziconotide solution.

CSF and Plasma

Intranasal
Ziconotide with
chitosan

Intranasal
Ziconotide
without chitosan
(Control)

Intravenous
Ziconotide

Intrathecal
Ziconotide

Group I

Group II

Group III

Group IV

In case of rats belonging to groups (I, II, III & IV) the time course of drug in the CSF was
investigated by collecting CSF from cisterna magna. At the same time blood samples were
collected at 15, 30, 60, 120, 180, 240 and 360 min from retro-orbital plexus using heparinized
capillary tubes. Plasma was collected from blood samples by centrifuging at 1500 rpm for 15
min and ziconotide was analyzed using HPLC and gamma counter after extraction.
4.2.10. Collection of CSF
Step 1: All the instruments used were clean and sterilized.
Step 2: The head was shaved after anesthetizing the rat with ketamine/xylazine.
Step 3: The animals were placed in supine position and the intranasal formulations were
administered using a microsyringe coupled with a soft polymer capillary directly into the
posterior region of the nasal cavity.
Step 4: The animals were placed on a stereotaxic frame (Harvard Instruments, Holliston, MA,
USA) and were locked by placing the ear bars into the ear canals. Firm placing of the animal was
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confirmed when there is no lateral movement of the head.
Step 5: The incisor bar was placed on the fore head of the rat so as to place the head at around
an inclination of 450. The nose clamp was then tightened.
Step 6: An incision was made on the skin over the occipital bone and the first layer of the muscle
was cut using a scalpel blade.
Step 7: A capillary tube with a pointed edge was connected to a 1 mL syringe with the aid of
tubing was used for a cisternal puncture.
Step 8: Following i.v or intranasal administration of ziconotide solution (25 µg in 100 µL) the
CSF samples were collected at 15, 30, 60, 120, 180, 240, 300 and 360 min and quantified using
HPLC and gamma counter.
4.2.11. Data analysis
The statistical analysis was carried out using GraphPad Prism 5 software. The t-test was selected
as the test of significance, and p<0.05 was considered statistically significant.
4.2.12. Pharmacokinetic data analysis
The area under the CSF concentration-time curve (AUC) from the start of drug administration to
the time of the last quantifiable concentration in CSF (AUC0-last) was calculated by using the
trapezoidal rule. The AUC0-∞ was derived by extrapolating the area to infinity by adding the last
quantifiable concentration in C(t-last) /Ke to AUC0-t, where Ke is the elimination rate constant. The
terminal half-life (t1/2) was quantitated by linear regression of the concentration-time curve on a
semi logarithmic scale by ln(2)/Ke. The pharmacokinetic parameters between the groups were
compared by t-test (considered significant if p value<0.05).
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4.3. Results and Discussion
4.3.1. Quantitation of ziconotide
The lowest possible concentration of neat unlabeled ziconotide that was detected by HPLC with
the aid of UV detector at 212 nm was 10 µg/ml at a retention time of ~24.79 min. This may be
because of the weak chromophore of ziconotide. But, ziconotide when radiolabeled with 125I and
quantitated using a HPLC and gamma counter the limit of detection significantly reduced to 1.24
X 10-3 ng/mL. The free fractions of the 125I were separated collecting the fractions at regular time
intervals and the chromatogram representing the free

125

I and

125

I bound to ziconotide were

represented in the figure 9. Mass spectral analysis carried out for the fractions collected from 2-4
min confirm the separation of free Iodine (Figure 10).
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Figure 9. Chromatogram representing 125I and 125I ziconotide.
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Figure 10. Negative mode ESI-MS spectra of free Iodine acquired on a Waters synapt HDMS.
4.3.2. Stability of ziconotide in olfactory tissue homogenates and CSF
A large variant of enzymes are present in the olfactory mucosa. These enzymes act as a
protective layer and prevent accidental entry of toxins via nose to brain pathway [92]. Ziconotide
being a conopeptide in nature may be prone to enzymatic degradation. The nasal mucosal surface
has a variety of proteolytic enzymes which could result in degradation of peptide and protein
drugs. Therefore, the stability of ziconotide in the homogenate of the mucosal tissue was
investigated for a period of 6 h. Ziconotide was found to be stable for a period of 4 h. This may
be because of the over quantification of the enzymes extracted during homogenization of the
tissue.
CSF is a product obtained from the filtrate of plasma and membrane secretions. It is a clear,
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colorless fluid with a composition of various ions, proteins, enzymes and other substances [93].
The stability of the ziconotide in freshly spiked rat CSF was investigated for a period of 6 h. The
ziconotide was found to be stable for the entire study period which may be because of the
complex structure of the peptide.
4.3.3. Kinetics of ziconotide in CSF- Intrathecal and Intravenous route of administration
Ziconotide was administered into the lumbar region of the spinal cord via intrathecal route. The
Cmax of ziconotide in 15 min following intrathecal route was found to be 992.2 ± 76.43 ng/ml.
The elimination rate constant of ziconotide in CSF was found to be 1.01 ± 0.34 h-1 which was
thought to be predominantly due to metabolism and elimination of drug. However, when the
physicochemical and enzymatic stability of the drug was studied in vitro using freshly aspired rat
CSF at 370C, the drug was found to be stable throughout the incubation period of 6 h. Therefore,
the high fluid turnover rate of CSF is the most likely reason for rapid disappearance of drug from
the CSF. Some of the other drugs used in the treatment of pain management were also reported
to have a short elimination half-life predominantly due to the rapid turnover of CSF. Vigdis and
coworkers [94] reported that sufentanil when administered intrathecally in humans has a short
half-life of 0.6 h and a low mean residence time of 0.9 h in CSF. Similarly, morphine was also
found to have shorter half-life of ~1.2 h in CSF when administered intrathecally [95, 96].
Ziconotide when administered via intravenous route the Cmax and Tmax in CSF were found to be
37.78 ± 6.8 ng/mL and ~2 h respectively. The AUC0-6 of ziconotide in CSF following i.v
administration was found to be 4.985 ± 0.977 min.µg/mL (100 µg/kg dose). The poor
bioavailability may be because of the poor ability of the ziconotide to cross the blood-csf barrier.
Blood-csf barrier is an interface formed by the epithelial cells of the choroid plexus and behaves
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like an inert lipoid membrane [97, 98]. From the PK data in figure 11, it appears that blood-CSF

Concentration of ziconotide in
CSF (ng/mL)

barrier strongly limits the bioavailability of ziconotide into the CSF.
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Figure 11. Pharmacokinetics of ziconotide in the CSF following intrathecal (●) and intravenous
(▲) administration.
4.3.4. In vitro permeation studies
In vitro permeation studies were carried out to determine the ability of ziconotide to permeate
across the olfactory mucosa. The amount of ziconotide permeated across the olfactory mucosa in
presence of ziconotide solution (Control) following 2 h was found to be 294.77 ± 82.43 ng/cm2.
Based on the studies carried out earlier in our group it was evident that chitosan acts as a
permeation enhancer for both small (Cefotaxime) and macro molecules (NGF and BDNF).
Chitosan used in concentrations of 0.1, 0.25 and 0.5 % w/v enhanced the permeation of
ziconotide across bovine olfactory mucosa by ~5, 13 and 16 fold at the end of 2 h respectively,
over control (294.77 ± 82.43 ng/cm2) (Figure.12).
Generally with the increase in concentration of the polymer, the viscosity increases reducing the
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diffusion coefficient and thus the permeation across the membrane. In this case, it appears that
the concentration dependent effect of chitosan on the membrane is predominant over the
influence of viscosity. However, 0.25% w/v solution was used in vivo to investigate the
pharmacokinetics of ziconotide following intranasal administration to minimize the potential

Cummulative amount of
ziconotide permeated across
olfactory mucosa (µg/cm2)

discomfort to the animal and blockade of respiratory pathway at higher concentration.
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Figure 12. In vitro permeation of ziconotide across the bovine olfactory mucosa in presence of
control (♦), 0.1% chitosan (■), 0.25% chitosan (▲) and 0.5% chitosan (●).
4.3.5. Pharmacokinetics of ziconotide in CSF following intranasal route
The Cmax of ziconotide in the CSF following intranasal administration of ziconotide with chitosan
was 7 fold higher than control (neat ziconotide) (33.55 ± 7.39 ng/mL) (Figure 13). But the
amount of ziconotide in CSF following i.v. administration (37.78 ± 6.8 ng/mL) was comparable
to that of intranasal control. A similar study comparing the administration of different molecular
weight fluorescein isothiocyanate dextrans (FD) via intranasal and i.v route was carried out by
Sakane and coworkers [64]. FDs with a molecular weight from 4-20 kD were detected in CSF
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following intranasal administration and were not detected following i.v administration. This
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could be because of the low permeability of the FDs across the blood-CSF barrier.
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Figure 13. Pharmacokinetic profile of ziconotide in CSF following intranasal administration of
ziconotide with chitosan (■), without chitosan (♦) and intravenous (▲) administration of
ziconotide.
The difference in Cmax attained following intranasal administration of neat ziconotide and
ziconotide with chitosan is likely due to the ability of chitosan to open the tight junctions present
in the olfactory epithelia. Chitosan also has the ability to act as a mucoadhesive agent and would
retain the drug for a longer period of time compared to the control, protecting from normal
mucosal clearance.
In case of the group administered with ziconotide along with chitosan the bioavailability (AUC06)

of ziconotide in CSF following intranasal administration was ~2 fold greater than the

bioavailability (AUC0-6) following i.v administration (4.98 ± 0.98 min.µg/mL). Whereas, the
bioavailability of neat ziconotide following intranasal administration (1.57 ± 0.44 min. µg/mL)
was ~ 3 fold less compared to bioavailability (AUC0-6) following i.v administration (Table 2).
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The time required to attain maximum concentration (Tmax) in CSF was less upon intranasal
administration (15 min) compared to i.v administration (120 min). Similar observations have
been reported in case of cephalexin. Sakane and co-workers [81] suggested that following
intranasal administration of cephalexin, the drug CSF levels were higher in 15 min than at 30
min. It was reported that the rapid absorption of drug may be due to the rapid distribution of the
drug into the cervical lymph node via the perineural spaces of the olfactory neurons [81].
Table 2. PK parameters of ziconotide in CSF following intranasal and intravenous
administration.

CSF

Intranasal
ziconotide

AUC0-6 (min.µg/mL)

1.57 ± 0.44

Intranasal
ziconotide with
Chitosan
10.73 ± 2.92

C max (ng/mL)

33.55 ± 7.39

244.34 ± 48.6

37.78 ± 6.8

T max (min)

15

15

120

KE (h-1)

0.54 ± 0.08

0.69 ± 0.17

0.43 ± 0.10

Intravenous
ziconotide
4.98 ± 0.98

Ziconotide at concentrations of 1-30 nM has the ability to reduce the electrically stimulated
responses. From figure 13 it is evident that the drug delivered via intranasal route in presence of
chitosan attained a concentration of 244.34 ± 48.6 ng/mL (92 nM) in 15 min. The Cmax of
ziconotide in human CSF following one hour intrathecal administration of 1-10 µg was found to
be 16.4-132 ng/ml (6.215-50 nM). The higher dose in case of intranasal solutions might be the
reason for higher CSF levels. Similar differences in CSF levels were reported in case of
melatonin spray administered in varying doses via intranasal route in humans and rats [99].

31

The production or turnover rate of CSF is about 125 µl/h in rats [100]. This might contribute to
considerable level of elimination of drug from the CSF. The elimination rate of ziconotide in
CSF following intranasal and intravenous administration is 0.6 ± 0.17 h-1 and 0.42 ± 0.1 h-1
respectively. The high elimination rate of ziconotide in CSF following intranasal and intravenous
administration may be because of the high turnover rate. Sakane et al investigated the ability of
cephalexin to reach CSF via intranasal administration and speculated that the high turnover rate
of CSF in rats may be reason for faster elimination of hydrophilic compounds like cephalexin
[81].
Although, the onset of action via intranasal route is rapid, the elimination of ziconotide from
CSF is also considerably high because of its high turnover rate. Despite high turnover rate
(Figure 14), intranasal route may still be preferred over i.v route because of noninvasiveness,
opportunity for frequent administration, and potentially minimal side effects.
4.3.6 Pharmacokinetics of ziconotide in plasma
The AUC0-6 levels in the plasma following intranasal administration of ziconotide with and
without chitosan were 54.84 ± 5.11 µg.min/mL and 27.88 ± 9.18 µg.min/mL, respectively.
These levels were almost 10 and 5 fold less compared to that of i.v administration (275.07 ±
23.44 µg.min/mL) (Figure 14). This data suggests that low systemic bioavailability following
intranasal administration is likely to result in less systemic side effects compared to parenteral
administration.
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Figure 14. Pharmacokinetic profile of ziconotide in plasma following intranasal administration
of ziconotide with chitosan (■), without chitosan (♦) and intravenous (▲) administration of
ziconotide.
Table 3. PK parameters of ziconotide in plasma following intravenous and intranasal
administration.

27.88 ± 9.18

Intranasal
ziconotide with
Chitosan
54.84 ± 5.11

275.07 ± 23.44

C Max (ng/mL)

153.19 ± 64.71

364.40 ± 68.74

1579.36 ± 374.15

T Max (min)

60

60

15

KE (h-1)

0.27 ± 0.12

0.39 ± 0.14

0.17 ± 0.48

Plasma

Intranasal
ziconotide

AUC0-6 (min.µg/mL)

Intravenous
ziconotide

4.4. Conclusion
Intranasal route could be utilized as one of the potential routes for delivery of ziconotide to the
CSF. These results indicate that significant drug levels were achieved in CSF following
intranasal administration.
33

5. IN SITU GEL FORMING INTRANASAL FORMULATIONS

A number of formulation strategies have been adopted to enhance the bioavailability of
therapeutics across the nasal mucosa, which increases the epithelial permeability,
mucoadhesiveness or residence time [101]. Polymers with high molecular weight and flexible
chains are used as bioadhesives, they have the capability to interact with mucin by forming
hydrogen, electrostatic, hydrophobic or van der waals interactions [102, 103]. Some bioadhesive
formulations not only increase the residence time in the nasal mucosa but also enhance the
stability of therapeutics [104]. The capabilities of the polymers will be gauged by their potential
to retain and release, interact with mucosal surface and biocompatibility with the tissue.
Thermoreversible polymers have the capability to exist in both sol and gel form at low and high
temperatures respectively, and are referred as in situ gels [105, 106]. Because of its dual nature,
it can be used as drug carrier for intranasal delivery where the therapeutics will be administered
in the solution form at low temperatures and turns to semi-solid gels with change in
physiological temperature [105]. These polymers compared to the existing liquid or powder
dosage forms have high viscosity, release drug slowly for a prolonged period, and has a higher
time of contact at the absorption site.
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6. POLOXAMER

Poloxamer is a triblock copolymer made up of poly(ethylene oxide)/ poly(propylene oxide)/
poly(ethylene oxide) (PEO/PPO/PEO) [107]. The PPO and PEO groups present in the polymer
are hydrophobic and hydrophilic respectively. Poloxamer has been widely used in formulating
drug delivery systems like gels, poloxamer-coated nanoparticles, o/w emulsions and solid
polymer blends because of its low toxicity, high solubility and bioadhesion characteristics [108110]. These polymers are soluble in aqueous, polar and non-polar solvents and are extremely
stable in presence of acids, alkalis and metal ions. Apart from all these advantages poloxamers
are also mucoadhesive and have the capability to convert from a liquid to gel at body
temperature [111, 112]. At low temperatures the hydration layer surrounds the poloxamer,
whereas, the hydrophobic portion is separated by the hydrogen bonding. But with a rise in
temperature, hydrogen bonds break and result in desolvation of the hydrophilic chains.
Desolvation leads to micellization and formation of more closely packed viscous gel [113].
Combination of these polymers with other mucoadhesive polymers like chitosan, polycarbophil,
PEO are more advantageous as the combination modifies properties like release, gelation
temperature, viscosity and mucoadhesiveness.
Perez and coworkers [114] successfully delivered naked siRNA and poloxamer polymers, as in
situ mucoadhesive gels to brain via olfactory epithelium. Chen and coworkers [115] could
successfully enhance effect of radix bulperi and retain its effect for a longer time in CSF
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following administration of temperature sensitive in situ gels. Poloxamer 407 has neither shown
irritations nor sensitivity and is being widely used in topical, nasal and ocular formulations [116].
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7. FORMULATION AND EVALUATION OF IN SITU INTRANASAL GELS FOR
DELIVERY OF ZICONOTIDE TO CSF

7.1 Objectives of the project
Specific Aim 1: To develop and evaluate in situ gel forming intranasal formulations using
thermosensitive poloxamers (Kolliphor P 407).
Poloxamers are triblock copolymers which are in solution form at low temperature and behave as
gels at body temperature. These polymers potentially prolong the drug release, protect the drug
from mucosal peptidases and reduce the mucociliary clearance. The poloxamers along with
chitosan was investigated for rheological characteristics, in vitro release and permeation across
olfactory mucosa.
Specific Aim 2: To investigate the pharmacokinetics of ziconotide in CSF, following
intranasal administration of formulations.
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Figure 15. Experimental plan of ziconotide in situ intranasal gels.
7.2. Materials and Methods
7.2.1 Chemicals
Ziconotide acetate was purchased from Sigma Aldrich and was radio labeled using 125I by Perkin
Elmer (Waltham, MA). Poloxamer 407 (Kolliphor P 407, KP 407) was kindly donated by BASF.
Chitosan (MW ~250 kDa, 75-80% deacetylation), Krebs-Ringer bicarbonate (KRB) buffer
(premixed powder), acetone, HCl were procured from Sigma chemicals (St. Louis, MO). Sodium
perchlorate, methanol, trifluoroacetic acid and acetonitrile were obtained from Fisher Scientific
(Atlanta, GA).
7.2.2. Preparation of in situ gel forming formulations of ziconotide
In situ gel was prepared by cold method on weight/weight basis. KRB was cooled to 40C and
appropriate amount of KP 407 was added and kept for stirring overnight in the refrigerator. Neat
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unlabeled ziconotide was added to the prepared polymeric solution.
Chitosan (40 mg) was dissolved in 165 µL of glacial acetic acid and 835 µL of KRB. This was
added to 9 mL of 30% KP 407 and was stirred overnight in the refrigerator. To 10 mL of
polymeric solution 2.5 mg of unlabeled neat ziconotide was added. The prepared polymeric
solution was further diluted with 125I ziconotide (18 µL of 125I ziconotide was added to 82 µL of
the neat unlabeled ziconotide polymeric solution (250 µg/mL)).
In case of control 2.5 mg of unlabeled neat ziconotide was added to 10 mL of 27% KP 407 and
kept for stirring overnight at 40C. The obtained polymeric solution was further diluted with

125

I

ziconotide (18 µL 125I ziconotide was added to 82 µL of the unlabeled neat ziconotide polymeric
solution (250 µg/mL)).
7.2.3. Rheological Characterization
Rheological studies were carried out using a TA HR2 rheometer (TA instruments, New Castle,
DE) equipped with 25 mm parallel plate. Temperature was controlled by using the peltier stage
connected to the rheometer. The effect of chitosan addition on gel strength, gelation temperature,
and apparent viscosity was determined using oscillatory shear rheology. Samples were subjected
to equilibration for a period of 5 minutes prior to analysis and each sample was examined in
triplicates.
a). Gelation temperature
Oscillatory rheometer was used to examine the gelation temperature (Tsol/gel) of the in situ
forming gels. The samples were subjected to a constant strain (0.5%) and frequency (0.5 Hz)
[114]. The elastic modulus (G’) was determined by increasing the temperature in a stepwise
manner from 100C to 370C at a heating rate of 30C. The phase transition from liquid to gel
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(Tsol/gel) was obtained by determining the inflexion point of G’.
b). Complex viscosity
The complex viscosity of the in situ gels was determined at a constant frequency of 0.5Hz and at
different temperatures increased from 100C to 370C at a heating rate of 30C.
c). Gel strength
Elastic modulus (G’) is an indirect measure of the gel strength. The elastic modulus (G’) was
determined by increasing the temperature in a stepwise manner from 100C to 370C at a heating
rate of 30C. The strength of in situ gels with and without chitosan at different temperatures
(100C-370C) and an angular frequency of 0.5Hz were examined.
7.2.4. Mucoadhesion evaluation of the gels
The adhesion of in situ gels was determined using Texture Analyzer 1 equipped with a 50-kg
load cell (TA.XT2i, Technologies Corp., Scarsdale, NY/ Stable Micro Systems, Godalming,
Surrey, UK). The texture analyzer was fitted with a TA-57R probe. The polymeric solution was
filled in a glass vial and allowed to gel at 340C. The probe was lowered to a height of 25 mm
(from the surface of the glass vial) at a speed of 0.5 mm/s with a trigger force of 5 N. The probe
was in contact with the gel for a period of 60 s and then was pulled back to its original height at a
post test speed of 10 mm/sec and the force required to withdraw the probe from the gel was
recorded as peak force. The area under the curve (AUC) that represents the work of adhesion
was determined from the force deflection profiles. The parameters were recorded in triplicate and
interpreted using Texture ExpertTM software.
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7.2.5. Analytical Method
a). Quantification of unlabeled neat ziconotide
The HPLC system (Waters, 1525) consisting of a Phenomenex C-18 analytical column (4.6 mm
X 150 mm, Luna 5.0 µ) and a variable wavelength detector (Waters, 2487). The mobile phase
was made up of a gradient elution starting with 100% mobile phase A for 2 minutes, shifting to
70% mobile phase A:30% mobile phase B over 12 minutes, then to 30% mobile phase A:70%
mobile phase B for next 10 min, and to 100% mobile phase A for approximately 6 minutes to reequilibrate the column. The flow rate was 1.0 mL/min and the column effluent was monitored at
212 nm. Mobile phase A consisted of 98% 25 mmol/L sodium perchlorate, 2% methanol, and
0.05% trifluoroacetic acid; mobile phase B consisted of 49.95% acetonitrile, 49.95% water, and
0.1% trifluoroacetic acid.
b). Quantification of 125I ziconotide
The samples were quantitated using both HPLC and gamma counter. Samples were injected onto
a HPLC column using the same conditions mentioned above. The fractions eluted from the
column were collected at regular intervals to separate free iodine from the iodine that is bound to
the peptide. The fractions collected every minute were quantitated for radioactivity using a
Beckman Gamma counter [117].
7.2.6. In vitro release studies
In vitro release studies were carried out using vertical Franz diffusion cells (Logan Instruments
Ltd, NJ). A spectra pore membrane with a cut of molecular weight 5kD was used to carry out the
release studies. The donor and receiver compartments were filled with 0.1 ml of the drug
polymeric solution and 5 mL of KRB respectively. The temperature of the chamber was
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regulated at 34 ± 10C by water circulation. The receiver compartment buffer was sampled at
different time points and the amount of ziconotide was quantified by HPLC and gamma counter.
7.2.7. In vitro permeation studies
Bovine olfactory mucosa was mounted on a Franz diffusion cell (Logan Instruments Ltd, NJ,
US) with an active diffusion area of 0.64 cm2 to carryout in vitro permeation studies. The
temperature of the chamber was regulated at 34 ± 10C by water circulation. The donor and
receiver compartments were filled with 500 µL and 5 mL of KRB respectively. Ag/AgCl wire
electrodes (Alfa Aesar, Wardhill, MA) with a diameter of 0.5 mm were fixed at a distance of 2
mm from the mucosa in donor and receiver compartment. The electrical resistance across the
mucosa was measured to determine the intactness of the mucosa using a digital multimeter and
waveform generator.
The donor compartments were then replaced with 0.1 mL of polymeric solutions, allowed to
equilibrate for a period of 5 min at 340C (nasal mucosal temperature) for the polymer to gel.
Samples were collected from the receiver compartment at regular intervals of time and were
estimated for ziconotide using HPLC and Gamma counter.
7.2.8. Pharmacokinetic studies
Pharmacokinetic studies were carried out in Sprague dawley rats (male, 250-300 g; Harlan
Company, Indianapolis, IN). The experimental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at the University of Mississippi (Protocol # 12-007).
The rats were divided into two groups (Group I and II). Each group was further divided into
seven groups (0.25, 1, 2, 4, 6, 9 and 12 h) (n=3 for each group). The rats were anesthetized using
ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p injection). Polymeric solution of ziconotide
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(100 µg/kg) with (ZKP-0.25C) and without 0.25% w/v chitosan (ZKP) was administered by
intranasal route (i.e. administration of drug directly into the posterior segment of the nose using a
microsyringe connected with a soft polymer capillary) to rats in groups I and II respectively.
Table 4. Distribution of rats for pharmacokinetic studies of ziconotide in CSF and plasma
following intranasal administration of in situ forming intranasal formulations.
Time

Intranasal Ziconotide
KP 407 with Chitosan
(ZKP-0.25C)

Intranasal Ziconotide
KP 407 without
chitosan (ZKP)

CSF and Blood

Group I

Group II

Both blood and CSF were collected from each group at respective time points. Plasma and CSF
were analyzed using HPLC and gamma counter.
7.3. Results and Discussion
7.3.1. Rheological evaluation
Preliminary studies showed that a minimum of 18% w/w KP 407 is required to obtain a gel at a
temperature lower than 370C. A gel may be formed at room temperature if the gelation
temperature is lower than 250C and may exist as a solution if gelation temperature is higher than
350C. As the concentration of the KP 407 increases the gelation temperature decreases. The
temperature of the nasal cavity is ~340C and a polymeric solution that gels close to nasal
temperature would be ideal. Further studies were carried out to determine a poloxamer
concentration that gels in the range of 250C to 370C. The gelation temperatures of 18, 20 and
22% KP 407 were found to be ~31, 28 and 220C respectively (Table 5 and Figure 16). The
gelation of KP 407 occurs as a result of change in polymer desolvation and subsequent
micellization. As the temperature increase the negative coefficient of the solubility effects
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micellization, expels the water from the core of micelles, leads to conformational changes in
methyl group (PPO) orientation and results in formation of gel [113, 118-120].
Table 5. Gelation temperature, storage modulus and complex viscosity of 18, 20 and 22% KP
407.
Poloxamer
Concentration
(%w/w)
18% KP 407

Gelation
Temperature (0C)

Storage Modulus
(Pa) @ 34 0C

Complex Viscosity
(Pa.s) @ 34 0C

31

5311 ± 25

1153 ± 41

20% KP 407

28

9366 ± 61

1976 ± 74

22% KP 407

22

14654 ± 110

3085 ± 94

The viscosity of 18, 20 and 22% KP 407 at 34 0C was found to be 1153 ± 41, 1976 ± 74 and
3085 ± 94 Pa.s, respectively. Chen et al reported that KP 407 in concentrations that gel at
physiological temperature, possess higher viscosity than normal nasal fluid, fast phase switching
capability and withstand the antidilution effect [115].
Gel strength is an indirect measurement of storage modulus (G’). The gel strength of 18, 20 and
22% KP 407 at an angular frequency of 0.5Hz and 340C were found to be 5311 ± 25, 9366 ± 61
and 14654 ± 110 Pa respectively (Figure 16). The gel strength increased with increase in the
concentration of KP 407.
KP 407 with 20% w/w was considered for further studies as it has a close gelation temperature to
physiological temperature, considerable gel strength and a viscosity higher than nasal mucosa
was considered for further studies.
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Figure 16. Determination of gelation temperature, storage and loss modulus of 18% (■,□), 20%
(●,○) and 22% (▲,Δ) KP 407.Closed markers represent storage modulus and open markers
represent loss modulus.
7.3.2. Mucoadhesiveness
Chitosan was found to enhance the permeation of ziconotide across the olfactory mucosa in our
preliminary studies. Chitosan at a concentration of 0.25 and 0.5% were incorporated in ZKP and
were evaluated for mucoadhesiveness using texture analyzer. There is a significant difference in
work of adhesion (p<0.05) when ZKP-0.25C and ZKP-0.5C are compared with ZKP. However,
there was no significant difference in work of adhesion between ZKP-0.25C and ZKP-0.5C.
Table 6. Adhesion properties of KP 407 with and without chitosan.
Peak Force(N)

Cohesion

20 % KP 407 (ZKP)

0.14 ± 0.02

89.8 ± 10.43

Work of Adhesion
(N.mm)
1.19 ± 0.09

20 % KP 407-0.25 % Chitosan
(ZKP-0.25C)
20 % KP 407-0.5 % Chitosan
(ZKP-0.5C)

0.15 ± 0.01

97.9 ± 11.32

1.41 ± 0.11

0.16 ± 0.01

99.8 ± 13.76

1.75 ± 0.26
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7.3.3 Effect of chitosan on gelation temperature, gel strength and viscosity
The influence of chitosan on gelation temperature, gel strength and viscosity were also
examined. Chitosan when added in a concentration of 0.25 % w/v shifted the gelation
temperature of 20% KP 407 from 300C to ~340C respectively. A similar change in temperature
on addition of chitosan was also reported by Zaki et al [12]. Besides increase in gelation
temperature the gel strength and the complex viscosity of the gels were decreased on addition of
chitosan (Table 7). Although the viscosity of the formulation decreased it was still higher than
the nasal mucosal viscosity which ranges between 0.02-500 Pa.s at a frequency of 0.01 -100
1/sec [121].
Table 7. Gelation temperature, gel strength and complex viscosity of 20% KP 407 with 0.25%
chitosan.

20% KP 407-0.25%
Chitosan

Gelation
Temperature (0C)

Storage Modulus
(Pa) @ 34 0C

Complex Viscosity
(Pa.s) @ 34 0C

34 ± 0.21

7578 ± 94

1605.46 ± 38

7.3.4. In vitro release and permeation studies
The percentage of ziconotide released from ZKP and ZKP-0.25C in 6 h was found to be 85.01 ±
0.86 and 69.22 ± 1.04 (Figure 17).
Chitosan used in concentration of 0.25 % w/v enhanced the permeation of ziconotide across the
bovine olfactory mucosa by ~5 fold at the end of 6 h compared to ziconotide alone (1.06 ± 0.09
µg/cm2) (Figure 18). Therefore, ZKP & ZKP-0.25C were used to carry out the in vivo studies
following intranasal administration.
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Figure 17. In vitro release studies of ziconotide KP 407 (■) and KP 407 chitosan (♦) gels.
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Figure 18. In vitro permeation studies of ziconotide KP 407 (■), KP 407 chitosan (♦) gels and
ziconotide solution in PBS (●) across bovine olfactory mucosa.
7.3.5. Pharmacokinetics of ziconotide in CSF
The Cmax of ziconotide in the CSF following intranasal administration of ZKP-0.25C was ~ 2
fold higher than ZKP (24.92 ± 2.91 ng/mL). Whereas, the amount of ziconotide in CSF
following intranasal administration of ziconotide solution with chitosan was ~5 fold higher than
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ZKP-0.25C (50.21 ± 3.48 ng/mL). The difference in Cmax attained following administration of
solution and gel formulation could be due to enhanced viscosity of gel formulation compared to
solution.
The AUC0-6 of ziconotide in CSF following intranasal administration of ZKP-0.25C was ~2 fold
greater than the AUC0-6 following intranasal administration of ZKP (6.08 ± 0.89 X 103
min.ng/mL) (Figure 20). Whereas, the AUC0-6 of ziconotide following administration of
intranasal chitosan solution (10.73 ± 2.92 X 103 min.ng/mL) was not statistically different from
the AUC0-6 following intranasal administration of ZKP-0.25C (13.02 ± 0.88 X 103 min.ng/mL) .
The time required to attain maximum concentration (Tmax) in CSF in case of ZKP and ZKP0.25C was found to be ~120 min. This is approximately 8 times higher than the Tmax attained
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Figure 19. Pharmacokinetic profile of ziconotide in CSF following intranasal administration of
ziconotide KP 407 without chitosan (■), with chitosan (♦) and ziconotide solution with chitosan
(●).
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Ziconotide at a concentration of 1-30 nM will be potential enough to block the synapses from Ntype calcium channels. From figure 20 it is evident that the ZKP and ZKP-0.25C could maintain
the ziconotide levels in CSF up to 9 h compared to ziconotide solution which maintained
therapeutic levels for a period of 3 h.
The elimination rate of the ziconotide from CSF is high because of the high turnover rate of the
CSF (125 ml/h) in rats. The elimination rate of ziconotide in CSF following intranasal gel was
reduced by ~7.5 fold compared to the elimination rate attained by intranasal solution (0.6 ± 0.17
h-1). The prolonged drug levels attained after ZKP and ZKP-0.25C gel administration may be
because of the reduced elimination rate.

Concentration of ziconotide in
CSF (ng/mL)

60
50
40
30
20
10
0
0

120

240

360
Time (min)

480

600

720

Figure 20. Pharmacokinetic profile of ziconotide in CSF following intranasal administration of
ziconotide KP 407 without chitosan (■), and with chitosan (♦).

49

7.3.6. Pharmacokinetics of ziconotide in plasma
The AUC0-6 levels of ziconotide in plasma following intranasal administration of ZKP-0.25C and
ZKP was found to be 37.89 ± 4.86 µg.min/mL and 31.77 ± 3.22 µg.min/mL (Figure 21). These
levels are almost 7 and 8 fold less compared to that of i.v administration (275.07 ± 23.44

Concentration of ziconotide in
plasma (µg/mL)

µg.min/mL).
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Figure 21. Pharmacokinetic profile of ziconotide in plasma following intranasal administration
of ziconotide KP 407 without chitosan (■), with chitosan (♦) and ziconotide solution with
chitosan (●).
7.4. Conclusion:
Ziconotide when delivered using poloxamer as a vehicle could not only attain therapeutic
concentration rapidly but also prolong the release of ziconotide and maintain therapeutic levels
in CSF till 9 h compared to solution. Prolonged maintenance of ziconotide would reduce the
frequency of administration. The clearance of ziconotide from CSF was also reduced
considerably

using

gel

formulations
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compared

to

intranasal

solutions.

Part II. INTRANASL DELIVERY OF CEFOTAXIME TO BRAIN
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8. CEFOTAXIME

Cefotaxime is a third generation cephalosporin recommended by WHO for treatment of bacterial
meningitis. It is generally administered via parenteral or oral route in large doses [122-124].
Systemic delivery of cefotaxime is associated with potential risk of causing severe systemic side
effects [125-127]. In addition to these, elimination half-life of cefotaxime in brain is short and
requires a frequent administration. Therefore, there is need for a patient compliant method to
deliver cefotaxime to the brain.
Meningitis is an inflammation caused in cerebrospinal fluid and meninges that surround the brain
and spinal cord. Neisseria meningitidis, Streptococus pneumonia, Haemophilus influenza type B
are three main bacterial species which accounts to three fourth of the meningitis infected world
population. Chloramphenicol and cephalosporins are administered in large doses to maintain
effective levels in the brain [125, 128, 129]. Apart from its high potency, the use of
cephalosporins is limited due to their high cost.
Nose to brain route has been investigated as a potential route for delivery of several small and
large molecular weight therapeutic agents [86, 90, 130, 131]. This pathway could deliver drugs
directly to the brain, bypassing the blood brain barrier (BBB) [84]. Moreover, intranasal delivery
would be noninvasive and allows frequent administration. Nasal drops can be self-administered
and do not require physician supervision during administration unlike in case of parenteral
formulations. Hence, nasal formulations are likely to reduce overall cost of the therapy.
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Therefore, in this project the plausibility of delivering cefotaxime to the brain via intranasal route
was investigated.
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9. FORMULATION AND EVALUATION OF CEFOTAXIME IN SITU INTRANASAL
GELS

9.1. Objectives of the project
Specific Aim 1: To develop novel intranasal drug delivery systems, incorporated with
chitosan to deliver cefotaxime to the brain.
The permeation of cefotaxime solution and cefotaxime-KP 407 gels across the olfactory mucosa
was investigated in presence and absence of chitosan. KP 407 gels exist as solution at low
temperature but are capable of turning into gel when encounters the olfactory mucosa (340C), to
facilitate prolonged drug delivery across the olfactory epithelium.
Specific Aim 2: To investigate the pharmacokinetics of cefotaxime in the brain and blood,
following administration of intranasal formulations.
Cefotaxime solution was administered to Sprague dawley rats via intranasal and i.v
administration. Whereas, cefotaxime KP 407 formulations with and without chitosan were
administered via intranasal route. Following administration of the formulations brain
microdialysis were carried out to determine the kinetics of the drug in brain. Blood plasma was
also collected to determine kinetics of the drug in the blood. The amount of cefotaxime present
in the dialysate sample (brain) and plasma were quantified using HPLC.
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9.2. MATERIALS AND METHODS
9.2.1. Chemicals
Cefotaxime sodium salt, chitosan (MW ~250 kDa, 75-80% deacetylation), KRB, 1-butanol,
potassium phosphate (monobasic) were procured from Sigma chemicals (St. Louis, MO).
Chloroform, phosphoric acid and acetonitrile were obtained from Fisher Scientific (Atlanta, GA).
9.2.2. Analytical Method
The HPLC system (Waters, 1525) consisting of a Phenomenex C-18 analytical column (4.6 mm
X 150 mm, Luna 5.0 µ) and a variable wavelength detector (Waters, 2487) was used. The mobile
phase was made up of 0.007 M phosphoric acid in water-acetonitrile (85:15 v/v). The flow rate
was 1.3 mL/min and the column effluent was monitored at 254 nm. The range of calibration
curve was 0.025 to 1 µg/mL (R2=0.99) [132].
9.2.3. In vitro permeation setup
In vitro permeation studies were carried out using vertical Franz diffusion apparatus (Logan
Instruments, Somerset, NJ). The olfactory mucosa was sandwiched between the donor and
receiver compartment such that the dorsal side of the tissue is facing the donor compartment and
the ventral side facing the receiver compartment. Ag/AgCl electrodes (procured from Alfa Aesar,
Ward Hill, MA) in the form of circular ring with a diameter of 0.5 mm were placed in the donor
and receiver compartment and were 2 mm away from the tissue in both compartments. A load
resistor RL (100 kΩ) was placed in series with olfactory mucosa after filling the donor and
receiver compartments with 500 µL and 5 mL of KRB respectively. The voltage drop across the
whole circuit (Vo) and across the mucosa (VE) was measured using a waveform generator and
multimeter (Agilent Technologies, Santa Clara, CA). The resistance in kΩ cm2 was measured by
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applying a small voltage of about 100 mv at 10 Hz [90].
9.2.4. Effect of chitosan on permeation of cefotaxime solution
The effect of different concentrations of chitosan (0.1% (CS-0.1C) and 0.25% w/v (CS-0.25C))
on the permeation of cefotaxime was investigated. Cefotaxime-chitosan solution was prepared by
dissolving the required quantity of chitosan in 1% glacial acetic acid solution in KRB followed
by addition of cefotaxime (1 mg/mL). Drug chitosan solution (500 µL) was placed in the donor
compartment and KRB was filled in the receiver compartment. Control set of experiments were
run only with cefotaxime (CS) without incorporation of chitosan in donor solution. The amount
of cefotaxime permeated across the olfactory mucosa was determined by analyzing the samples
collected from the receiver compartment by HPLC.
9.2.5. In vitro release studies of cefotaxime KP 407 gels
In vitro release studies were carried out using vertical Franz diffusion cells and a 0.5 kDa spectra
pore membrane as mentioned in the section 7.2.6. Cefotaxime KP 407 polymeric solution with
0.1 (CKP-0.1C), 0.25 (CKP-0.25C) & 0.5% chitosan (CKP-0.5C) and cefotaxime KP 407
without chitosan (CLF) were examined for their release profile. The receiver compartment buffer
was sampled at different time points and quantitated for cefotaxime using HPLC.
9.2.6. In vitro permeation studies of cefotaxime KP 407 gels
Bovine olfactory mucosa and Franz diffusion cells were used and the experimental procedure
carried out was same as mentioned above in section 7.2.7. Following the setup, the donor
compartments were filled with 0.5 mL of polymeric solutions, allowed to equilibrate for a period
of 5 min at 340C (nasal mucosal temperature) for the polymer to gel. Samples were collected
from the receiver compartment at regular intervals of time and were quantitated for cefotaxime
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using HPLC.
9.2.7. Extraction of cefotaxime from plasma
Blank plasma obtained from untreated rats was spiked with known concentrations of cefotaxime
and calibration curve was plotted using the analytical method as mentioned in section 9.2.2. The
rat plasma samples containing cefotaxime were extracted initially by vortexing 1 mL of plasma
with 0.5 ml of 0.4M HCl. Then 7 mL of chloroform-1-pentanol (3:1) was added to the mixture
and vortexed for 30 min followed by centrifugation at 40C for a period of 10 min at 1000 g. From
this bottom organic phase (5 mL) was collected and 350 µL of phosphate buffer (pH 7) was
added to it so as to back extract (30 min) the cefotaxime which was then centrifuged at 40C for a
period of 10 min. The upper aqueous phase was quantified by HPLC [133].
9.2.8. Calibration of microdialysis probe
Microdialysis probes (CMA 12) were calibrated in vitro by immersing the probes in dialysis
media containing cefotaxime (concentrations 25, 50 and 75 µg/mL). A syringe pump controller
(BASi, West Lafayette, IN) was used to continuously perfuse the KRB at a flow rate of 2.0
µL/min. The probes were equilibrated for a period of 30 min and then samples were collected at
regular intervals for a period of twelve hours. The percentage recovery was calculated as the
ratio of dialysate concentration to its concentration in the dialysis medium surrounding the probe.

9.2.9. In vivo brain microdialysis
Step 1) All the instruments used were clean and sterilized.
Step 2) The rats were anesthetized using ketamine/xylazine and the head was shaved.
Step 3) The animals were laid on their back and the formulations were administered intranasally
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using a microsyringe connected with a soft polymer capillary directly into the posterior segment
of the nose.
Step 4) After 30 minutes, the animals were placed on the stereotaxic frame (Harvard instruments, Holliston, MA) by putting the ear bars into the ear canals such that the animal is locked
correctly. This was confirmed as there was no lateral movement of the head.
Step 5) The front teeth of the rat was put over the incisor bar and was slided away from the
animal as far as possible to lock the head. The nose clamp was then tightened.
Step 6) The shaved part of head was cleaned with iodine and incision was made with a scalpel.
Using retractors the skull was exposed and epinephrine (100 µg/mL) was used to minimize
blood flow from the wound area.
Step 7) The skull was scraped to remove the adhering tissue so that bregma (reference point for
stereotaxic surgery of the brain) is easily distinguishable.
Step 8) The probe holder was adjusted such that its tip exactly points the bregma. The values of
the three coordinates (dorso-ventral, medio-lateral and anterio-posterior) were recorded by
reading the vernier scale.
Step 9) The appropriate coordinates for drilling a hole in the hippocampus region of the rat brain
were calculated.
Step 10) Using a dentist’s drill a hole was made carefully in the hippocampus region such that
the drill goes only through the skull without damaging the blood vessels.
Step 11) After drilling the hole, using a small needle the dura mater (the outermost layer of the
meninges surrounding the brain) was punctured.
Step 12) Microdialysis probe was fixed on to the probe holder and slowly inserted into the hole
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drilled in the hippocampus region (anterior-posterior = 5.6 mm, medio-lateral = 5 mm, dorsoventral = 7 mm, from bregma).
Step 13) Using a microinjection pump, the microdialysis probes were equilibrated by perfusing
KRB buffer at a rate of 2 µL/min for a period of one hour.
Step 14) The animals were given maintenance doses of anesthesia (ketamine 40 mg/kg &
xylazine 10 mg/kg) intravenously as needed.
9.2.10. Pharmacokinetic studies
Pharmacokinetic studies were carried out in Sprague dawley rats (male, 250-300 g; Harlan
Company, Indianapolis, IN, USA). The experimental procedures were approved by the
Institutional animal care and use committee (IACUC) at the University of Mississippi (Protocol
# 10-017). The rats were categorized into eight groups (n=6 for each group 1-8). The rats were
anesthetized using ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p injection).
Cefotaxime solution with 0.25% w/v chitosan (100 mg/kg) was administered by I.V route to rats
in groups 1 & 3 and intranasally (i.e. administration of drug directly into the posterior segment of
the nose using a microsyringe connected with a soft polymer capillary) to groups 2 & 4.
Whereas, cefotaxime KP 407 gels with and without chitosan were administered intranasally to
groups 5 & 6 and 7 & 8 respectively.
In case of rats belonging to groups (1, 2, 5 & 7)-= the time course of drug in the brain was
investigated by performing microdialysis. Rats in each group were further divided into two
groups A & B (Group A 0-6 h and Group B 6-12 h). The microdialysis probe (CMA 12) was
inserted into brain (anterior-posterior=5.6 mm, medio-lateral=5 mm, dorso-ventral=7 mm, from
bregma) after securing the rat on a stereotaxic frame (Harvard Instruments, Holliston, MA,
59

USA). The microdialysis probes were equilibrated by perfusing KRB at 2 µL/min for a period of
30 minutes with the aid of a microinjection pump. Following administration of i.v or intranasal
cefotaxime solution or intranasal gel (25 mg in 100 µL) the microdialysis fractions were
collected at 15, 30, 60, 90, 120, 180, 240, 300, 360 and 720 min and quantified using HPLC.
In case of groups 3, 4, 6 & 8 rats will be further divided into two groups each group possessing 3
rats. Blood samples were collected at 15, 30, 60, 90, 120, 180, 240, 300, 360 and 720 min from
retro-orbital plexus using heparinized capillary tubes ((Group A-15, 60, 120, 240 and 360 min)
and (Group B-30,90,180,300 and 720 min)). Plasma was collected from blood samples by
centrifuging at 1500 rpm for 15 min and cefotaxime was analyzed using HPLC after extraction
with HCl, chloroform-1-pentanol (3:1) and phosphate buffer solvent system.
9.2.11. Data analysis
The statistical analysis was carried out using GraphPad Prism 5 software. The t-test was selected
as the test of significance, and p<0.05 was considered statistically significant.
9.2.12. Pharmacokinetic data analysis
AUC was calculated using trapezoidal rule, Cmax and Tmax were directly obtained from the
concentration-time graphs.
9.3. RESULTS AND DISCUSSION
9.3.1. Effect of chitosan on permeation of cefotaxime
Chitosan (0.25% w/v) enhanced the permeation of cefotaxime across bovine olfactory mucosa by
~1.5 fold and ~2 fold at the end of 1st hour and 2nd hour respectively, over control (29.56 ± 6.18
µg/cm2). Whereas, there was no significant enhancement of cefotaxime permeation at 0.1% w/v
concentration of chitosan. Overall, the enhancement in permeability of drug by chitosan was not
60

as dramatic as that observed in case of NGF [90].
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Figure 22. Effect of chitosan 0.1% (♦) and 0.25%(■) over control (●) on in vitro permeation
studies of cefotaxime across bovine olfactory mucosa.
9.3.2. In vitro release studies of cefotaxime KP 407 gels

100

% Drug release

80
60
40
20
0
0

2

4

6
Time (h)

8

10

12

Figure 23. In vitro release studies of cefotaxime from CKP (▲), CKP-0.1C (●), CKP-0.25C (♦)
and CKP-0.5C (■).
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The percentage of cefotaxime released from the CKP, CKP-0.1C, CKP-0.25C and CKP-0.5 in 9
h was found to be 94.6 ± 2.33, 85.3 ± 3.69, 76.19 ± 4.43 and 62.22 ± 5.2 (Figure 23).
9.3.3. In vitro permeation of cefotaxime from solution and gel
The amount of drug permeated in six hours across the olfactory mucosa in case of CS-0.25C,
CKP-0.25C and CKP was found to be 2, 1.5 and 1.2 fold higher than the control ( 116.74 ± 29.59
µg/cm2), with a statistical significance of p<0.05 (Figure 24).
Therefore, CKP-0.25C and CKP was used for intranasal administration. Whereas, CS-0.25C was
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Figure 24. In vitro permeation studies of CS (●), CS-0.25C (■), CKP (▲) and CKP-0.25C (♦)
gels across bovine olfactory mucosa.
9.3.4. Pharmacokinetics of cefotaxime in the brain
The in vitro recovery of microdialysis probes was found to be 12.84 ± 1.42%. The Cmax of
cefotaxime in the brain following intranasal administration of CS (3.32 ± 1.13 µg/mL) was found
to be less than that observed upon i.v administration (5.46 ± 1.98 µg/mL). This difference in
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Cmax is likely because of drug loss due to absorption of a greater fraction of drug from nasal
mucosa into the systemic circulation followed by elimination via normal clearance. Such similar
kind of observations using tetramethylpyrazine were reported earlier by Hussian and co-workers
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as well as Illum [134, 135].
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Figure 25. Pharmacokinetics of cefotaxime in brain following intranasal administration of CS0.25C (■), CKP (▲), CKP-0.25C (♦) and intravenous CS (●).
The Cmax of cefotaxime in the brain following intranasal administration of CKP and CKP-0.25C
was found to be 1.11 ± 0.28 µg/mL and 2.43 ± 0.34 µg/mL (p value <0.05). These Cmax levels
are ~ 3 and 1.36 fold less compared to the Cmax levels attained following intranasal
administration of cefotaxime solution.
Moreover, the AUC0-6 of cefotaxime in the brain following intranasal administration of CS0.25C, and CKP was ~ 2 and 3 fold lower than the AUC0-6 following i.v administration (0.90 ±
0.06 X 103 min.µg/mL) (Figure 25). But the AUC0-6

of cefotaxime following intranasal

administration of CKP-0.25C (0.76 ± 0.06 X 103 min.µg/mL) was not significantly different
from AUC0-6 following i.v administration (p value > 0.05).
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However, the time required to achieve maximum concentration (Tmax) was less upon intranasal
administration of CS-0.25C (30 min) and CKP-0.25C (90 min) compared to i.v administration
(180 min). Similar observations have been reported in case of tetramethylpyrazine. Frey and coworkers [8] suggested that rapid absorption of drug via olfactory region could be due to
convective transport of drugs along the nose-brain pathway. The ability of intranasally
administered drugs to reach the brain relatively faster than the i.v route was previously reported
by Illum and co-workers in case of hydrophilic drugs [135]. Whereas the Tmax was attained in
case of CKP (180 min) was same as i.v administration.
The minimum concentration at which the drug has the ability to inhibit the bacterial growth is
defined as minimum inhibitory concentration (MIC). The MIC levels of cefotaxime against most
bacteria causing meningitis range from 0.01 to 0.6 µg/mL [127]. From figure 25 it is evident that
the drug delivered via intranasal route attained MIC levels rapidly and remained over MIC
through 6 h duration similar to that observed upon i.v administration. But the elimination rate
constant (Ke) was lowered by 2 and 5 fold in case of CKP-0.25C and CKP compared to CS0.25C. The reduction in elimination rate constant makes the drug reside in the brain for a longer
period of time compared to the solution and also reduces the frequency of administration.
Although the brain levels of cefotaxime are higher following i.v administration (Figure 22),
intranasal route may be preferred over i.v route because of noninvasiveness, rapid absorption,
potentially minimize systemic side effects and minimize frequency of administration by
administration of gels. Moreover, overshooting the MIC levels in the brain, as seen in case of i.v
route is not likely to improve the treatment but rather could cause toxicity in case of certain
drugs with small therapeutic window.
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9.3.5. Pharmacokinetics of cefotaxime in plasma

Figure 26. Pharmacokinetics of cefotaxime in plasma following intranasal administration of
intravenous CS (●). Insert picture shows pharmacokinetics of cefotaxime in plasma following
intranasal administration of CS-0.25C (■), CKP-0.25C (♦), and CKP (▲).

The recovery of cefotaxime from plasma was 39.60 ± 3.25%. The drug levels in the plasma
following intranasal administration were almost an order of magnitude less when compared to
that of i.v administration (Figure 26). The AUC0-6 levels following intranasal administration of
CS-0.25C, CKP-0.25C and CKP were ~ 15, 28 and 50 fold less than i.v administration 532.23 ±
193.42 X 103 min.µg/mL (p-value <0.05). This data suggests that the drug is likely to undergo
metabolism in the mucosal membrane. However, low systemic bioavailability following
intranasal administration is likely to result in less systemic side effects compared to parenteral
administration.
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9.4. Conclusion
These results indicate that intranasal route could be utilized as one of the potential routes for
delivery of cefotaxime to the brain. The effective drug levels could be achieved by increasing the
dose and the frequency of administration can be minimized by using gel formulations. The
intranasal administration of cefotaxime was also found to result in relatively low systemic
bioavailability. These results suggest that intranasal delivery of cefotaxime could be developed
as a potential treatment approach for bacterial meningitis.
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10. BIODEGRADABLE MULTIBLOCK COPOLYMER FOR IN SITU GEL
FORMULATION

Advances in smart polymeric materials lead to the development of bioresponsive drug delivery
systems that respond to temperature. These polymers are being considered as an effective
biomaterial for the drug delivery of small molecules, peptides and proteins [136-138]. Block
copolymers comprise of balanced hydrophilic and hydrophobic chains and undergo
thermosensitive phase transition in water [139]. The multiblock copolymers (MBCP) possess
enhanced rheological properties after thermally driven gelation and control the drug release via
in situ depot formation.
Dual-stimuli polymers which are thermogelling and undergo pH sensitive degradation have been
synthesized from Pluronic® F127 [140]. These exhibit pH sensitive micellization and thermo
reversible sol-gel transitions in water. MBCP is a novel triblock copolymer synthesized from
Pluronic® P104 and di-(ethylene glycol) divinyl ether (DEGDVE) [141].
Nasal mucosal temperature is reported to be ~340C with a physiological pH of 5.0-6.0. MBCP
was reported to have a gelation temperature in the range of 20-400C and undergoes selective
degradation at acidic pH.
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11. FORMULATION AND EVALUATION OF MULTI BLOCK COPOLYMER IN SITU
INTRANASAL GELS

11.1 Objectives of the project
Specific Aim 1: To develop and evaluate in situ gel forming intranasal formulations using
multi block copolymer (MBCP)
MBCP is a triblock copolymer is in the form of a solution at low temperature and behaves as gel
at body temperature. These polymers undergo selective degradation with response to acidic pH.
The MBCP along with chitosan was investigated for rheological characteristics, in vitro release
and permeation across olfactory mucosa.
Specific Aim 2: To investigate the pharmacokinetics of cefotaxime in brain, following
intranasal administration of MBCP in situ gel formulations.
11.2. Materials and Methods
11.2.1 Chemicals
Cefotaxime sodium salt, chitosan (MW ~250 kDa, 75-80% deacetylation), KRB, 1-butanol,
potassium phosphate (monobasic) were procured from Sigma chemicals (St.Louis, MO).
Chloroform, phosphoric acid and acetonitrile were obtained from Fischer Scientific (Atlanta,
GA).Krebs-Ringer bicarbonate (KRB) buffer (premixed powder), acetone, HCl were procured
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from Sigma chemicals (St.Louis, MO). Sodium perchlorate, methanol, trifluoroacetic acid and
acetonitrile were obtained from Fisher Scientific (Atlanta, GA). Pluronic® P 104 was provided
as gift samples from BASF chemical company (Florham Park, NJ). p-Toluenesulfonic anhydride,
anhydrous tetrahydrofuran (THF), 1, 6-diphenyl-1, 3, 5-hexatriene (DPH) and anhydrous toluene
were purchased from Acros Organics (Morris Plains,NJ). Di-(ethylene glycol) divinyl ether
(DEGDVE) was obtained from Aldrich (Milwaukee, WI).
11.2.2 Polymer synthesis
MBCP polymer was synthesized as described by Garipelli et al [141]. In brief, fifteen grams of
Pluronic® P 104 (MW 5900), and p-toluene sulfonic anhydride (0.03 molar equivalent to
Pluronic®) were dissolved in 150 mL of anhydrous toluene. The toluene(~100 mL) present in the
mixture was dried of by distillation. Following distillation, DEGDVE in a 1:1 molar ratio to
Pluronic® P 104 was added to the dry mixture. The reaction was carried out overnight by
magnetic stirring at 500C under dry nitrogen. Following an overnight reaction the reaction solution
was mixed with 150 mL of petroleum ether to precipitate polymer. The precipitated polymer was
then dissolved in a dilute NaOH solution at a 2:1 molar ratio of NaOH to p-TSA so as to achieve
a concentration of 15 wt% at 40C. The aqueous polymeric solution was subjected to heating at
750C so as to facilitate polymer precipitation. After dissolving the crude precipitated polymer in
distilled water at a concentration of 20 wt%, the polymer was precipitated again by heating. The
polymer was purified by another cycle of dissolving by cooling and precipitation by heating. The
final precipitate was freeze-dried to obtain white powder.
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11.2.3. Preparation of in situ MBCP gel forming formulations of cefotaxime
In situ gel was prepared by cold method on weight/weight basis. KRB was cooled to 40C and
appropriate amount of MBCP was added and kept for stirring overnight in the refrigerator.
Cefotaxime was added to the prepared polymeric solution.
Chitosan was dissolved in glacial acetic acid in appropriate amounts and was then added to the
MBCP polymeric solution to obtain the desired concentrations. Cefotaxime was then added in
required quantities to the MBCP polymeric solution. In case of control cefotaxime was added to
MBCP polymeric solution and kept for stirring overnight at 40C.
11.2.4. Rheological Characterization
Rheological studies were carried out using a TA HR2 rheometer (TA instruments, New Castle,
DE) equipped with 25 mm parallel plate. Temperature was controlled by using the peltier stage
connected to the rheometer. The effect of chitosan on gel strength, gelation temperature, and
apparent viscosity was determined using oscillatory shear rheology. Samples were subjected to
equilibration for a period of 5 minutes prior to analysis and each sample was examined in
triplicates.
a). Gelation temperature
Oscillatory rheometer was used to examine the gelation temperature (Tsol/gel) of the in situ
forming gels. The elastic modulus (G’) was determined by increasing the temperature in a
stepwise manner from 100C to 400C at a heating rate of 30C. The phase transition from liquid to
gel (Tsol/gel) was obtained by determining the inflexion point of G’.
b). Complex viscosity
The complex viscosity of the in situ gels was determined at a constant frequency and at different
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temperatures increased from 100C to 400C at a heating rate of 30C.
c). Gel strength
Elastic modulus (G’) is an indirect measure of the gel strength. The elastic modulus (G’) was
determined by increasing the temperature in a stepwise manner from 100C to 400C at a heating
rate of 30C. The strength of in situ gels with and without chitosan at different temperatures
(100C-400C) and angular frequency were examined.
11.2.5. Analytical Method
The analytical method is same as mentioned in section 9.2.2.
11.2.6. In vitro release studies
In vitro release studies were carried out using vertical Franz diffusion cells (Logan Instruments
Ltd, NJ). A spectra pore membrane with a cut of molecular weight 1kD was used to carry out the
release studies. The donor and receiver compartments were filled with 0.1 ml of the drug
polymeric solution and 5 mL of KRB (pH 5.5) respectively. The temperature of the chamber was
regulated at 34 ± 10C by water circulation. The receiver compartment buffer was sampled at
different time points and the amount of cefotaxime was quantified by HPLC.
11.2.7. In vitro permeation studies
In vitro permeation studies were carried as mentioned above in section 9.2.6
11.2.8. Extraction of cefotaxime from plasma
The extraction procedure was same as mentioned above in section 9.2.7
11.2.9. Calibration and In vivo brain microdialysis
The microdialysis was carried out as mentioned above in section 9.2.8 and 9.2.9
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11.2.10. Pharmacokinetic studies
Pharmacokinetic studies were carried out in Sprague dawley rats (male, 250-300 g; Harlan
Company, Indianapolis, IN, USA). The experimental procedures were approved by the
Institutional animal care and use committee (IACUC) at the University of Mississippi (Protocol
# 10-017). The rats were categorized into two groups (n=6 for each group). The rats were
anesthetized using ketamine (80 mg/kg) and xylazine (10 mg/kg) (i.p injection).
Cefotaxime (100 mg/kg) MBCP gels with 0.25% w/v chitosan and without chitosan were
administered intranasally (i.e. administration of drug directly into the posterior segment of the
nose using a microsyringe connected with a soft polymer capillary) to groups 1 and 2
respectively.
The time course of drug in the brain was investigated by performing microdialysis. Rats in each
group were further divided into two groups A & B (Group A 0-6 h and Group B 6-12 h). The
microdialysis probe (CMA 12) was inserted into brain (anterior-posterior=5.6 mm, mediolateral=5 mm, dorso-ventral=7 mm, from bregma) after securing the rat on a stereotaxic frame
(Harvard Instruments, Holliston, MA, USA). The microdialysis probes were equilibrated by
perfusing KRB at 2 µL/min for a period of 30 minutes with the aid of a microinjection pump.
Following administration of intranasal cefotaxime MBCP intranasal gel (25 mg of cefotaxime in
100 µL of MBCP gel) the microdialysis fractions were collected at 15, 30, 60, 90, 120, 180, 240,
300, 360 and 720 min and quantified using HPLC.
11.2.11. Data analysis
The statistical analysis was carried out using GraphPad Prism 5 software. The t-test was selected
as the test of significance, and p<0.05 was considered statistically significant.
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11.2.12. Pharmacokinetic data analysis
AUC was calculated using trapezoidal rule, Cmax and Tmax were directly obtained from the
concentration-time graphs.
11.3 Results
11.3.1 Rheological Evaluation
The preliminary studies carried out using test tube inverting method by Garipelli et al suggest
gelation of 10-20 % w/w MBCP at a temperature of ~30-40 0C. To further determine the exact
gelation temperature of the MBCP polymer that gels at a temperature close to nasal mucosa
rheology of the MBCP polymeric solutions was carried out to determine the gelation temperature
and complex viscosity.

Figure 27. Determination of gelation temperature, storage and loss modulus of 10% (■,□), 15%
(▲,Δ) and 20% (♦,◊) MBCP. Closed markers represent storage modulus and open markers
represent loss modulus.
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The results in figure 27 indicate that with increase in concentration of MBCP the gelation
temperature is dropping down. Nasal mucosal surface temperature is ~340C and a polymeric
solution that gels close to the nasal mucosal temperature would aid in ease of administration. The
gelation temperatures of 10, 15 and 20% MBCP were found to be ~37, 34 and 310C respectively
(Table 8). The gelation of MBCP may be because of the formation of different liquid crystalline
phases, isotropic/cubic phases and multi phases at low and high temperature respectively [141].
As the temperature increases the polypropylene glycol blocks gets dehydrated at a concentration
higher than CMC and leads to increased volume fraction of the micelles which results in sol/gel
transition.
Table 8. Gelation temperature, storage modulus and complex viscosity of 10, 15 and 20%
MBCP.
MBCP
Concentration
(%w/w)
10% MBCP

Gelation
Temperature (0C)

Complex Viscosity
(Pa.s)

Gel Strength (Pa)

37

30 ± 1.12

216.05 ± 10.41

15% MBCP

34

190 ± 8.41

1698 ± 25.32

20% MBCP

31

295 ± 6.21

2586.87 ± 24.54

The viscosity and gel strength of 10, 15 and 20% MBCP increased with increase in concentration
of MBCP. The complex viscosity of 10, 15 and 20 % MBCP was found to be ~ 30, 190 and 295
Pa.s. The gel strength of the 10, 15 and 20 % MBCP were found to be ~ 216, 1698 and 2586 Pa
respectively. Lower viscosity facilitates ease of administration whereas higher gel strength helps
to withstand the mucociliary clearance.
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Based on the obtained results 15% MBCP was selected for further studies and chitosan was
added. The effect of chitosan on the gelation temperature, viscosity and gel strength was
examined. With incorporation of 0.1, 0.25 and 0.5% w/w of chitosan the gelation temperature of
the 15% w/w MBCP lowered from 340C to ~ 31, 31 and 28 0C.
11.3.2 Effect of chitosan on gelation temperature, gel strength and viscosity
The influence of chitosan on gelation temperature, gel strength and viscosity were also
examined. Chitosan when added in a concentration of 0.25 % w/v shifted the gelation
temperature of 15% MBCP from 310C to ~280C respectively. The shift in gelation temperature
may be because of the increase in viscosity of the gel on addition of chitosan. The complex
viscosity and gel strength of the MBCP-0.25% chitosan at 340C were increased compared to
MBCP alone (Table 9).
Table 9. Gelation temperature, gel strength and complex viscosity of 15% MBCP and 15%
MBCP with 0.25% chitosan.
Polymer

Gelation
Temperature (0C)

Complex Viscosity
(Pa.s) @ 34 0C

Storage Modulus
(Pa) @ 34 0C

15% MBCP

31

190 ± 8.41

1698 ± 25.32

15% MBCP-0.25
chitosan

28

260 ± 4

2531 ± 12

A similar trend in shift of gelation temperature on addition of HPγCD complex was reported by
Kim and coworkers [136]. It was reported that the change in gelation temperature could be
because of the interaction of the hydrophilic hydroxyl groups (-OH) of the HPγCD with the
water molecules and resulting in a strong hydrogen bond with that of a crosslinked gel. The same
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mechanism may also be the reason for change in temperature of the MBCP on addition of
chitosan.
11.3.3 In vitro release of cefotaxime MBCP gels
The percentage of cefotaxime released from the MBCP, and MBCP-0.25C, in 9 h was found to
be 83.5 ± 3.22, and 74.84 ± 4.32 (Figure 28). The difference in release may be due to the
increase in viscosity which could be due to the incorporation of chitosan.
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Figure 28. In vitro release studies of cefotaxime from MBCP (■),and MBCP-0.25C (♦).
Similar release studies were carried out by Kim and coworkers [142] using Amphotericin B and
HPγCD in the presence of MBCP. The amount of amphotericin released following 12 h was
reported to be ~ 55%. This may be because of the higher concentration of the polymer used and
also because of the complex that is formed between amphotericin and HPγCD.
11.3.4 In vitro permeation of cefotaxime from solution and MBCP gel
The amount of drug permeated in four hours across the olfactory mucosa in case of CS-0.25C,
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and MBCP-0.25C were found to be 2, and 1.3 fold higher than the control ( 97.65 ± 16.56

Amount of cefotaxime permeated
across olfactory mucosa
(µg/cm2)

µg/cm2), with a statistical significance of p<0.05 (Figure 29).
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Figure 29. In vitro permeation studies of CS (▲), CS-0.25C (●), and MBCP-0.25C (■) gels
across bovine olfactory mucosa.

11.3.5. Pharmacokinetics of cefotaxime in the brain
The in vitro recovery of microdialysis probes was found to be 12.84 ± 1.42%. The recovery of
cefotaxime from plasma was 39.60 ± 3.25%. The Cmax of cefotaxime in the brain following
intranasal administration of CS (3.32 ± 1.13 µg/mL) was found to be less than that observed
upon i.v administration (5.46 ± 1.98 µg/mL). This difference in Cmax is likely because of drug
loss due to absorption of a greater fraction of drug from nasal mucosa into the systemic
circulation followed by elimination via normal clearance. Such similar kind of observations
using tetramethylpyrazine were reported earlier by Hussian and co-workers as well as Illum
[134, 135].

77

Concentration of cefotaxime in
brain (µg/mL)

8

6

4

2

0
0

60 120 180 240 300 360 420 480 540 600 660 720
Time (min)

Figure 30. Pharmacokinetics of cefotaxime in brain following intranasal administration of CS0.25C (▲), MBCP (■),MBCP-0.25C (♦) and i.v administration of cefotaxime (●).
The Cmax of cefotaxime in the brain following intranasal administration of MBCP and MBCP0.25C were found to be 2.41 ± 0.38 µg/mL and 1.22 ± 0.27 µg/mL. These Cmax levels are ~ 1.38
and 2.72 fold less compared to the Cmax levels attained following intranasal administration of
cefotaxime solution with chitosan.
The AUC0-12 of cefotaxime in the brain following intranasal administration of MBCP-0.25C
(0.748 ± 0.08 X 103 min.µg/mL) was ~ 1.66 fold higher than the AUC0-12 following intranasal
administration of CS-0.25C (Figure 30). But the AUC0-12 of cefotaxime following intranasal
administration of MBCP (0.416 ± 0.014 X 103 min.µg/mL) was not significantly different from
AUC0-12 following intranasal administration of CS-0.25C (p value > 0.05).
However, the time required to achieve maximum concentration (Tmax) was less upon intranasal
administration of CS-0.25C (30 min) compared to that of MBCP (120 min) and MBCP-0.25C
(180 min).
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The minimum concentration at which the drug has the ability to inhibit the bacterial growth is
defined as minimum inhibitory concentration (MIC). The elimination rate constant (Ke) was
lowered by 9 and 7 fold in case of MBCP-0.25C and MBCP compared to CS-0.25C (3.6 ± 0.72
h-1).
Although the brain levels of cefotaxime are higher following i.v administration (Figure 30),
intranasal route of gels may be preferred over i.v route because of rapid onset of action,
noninvasiveness, potentially minimize systemic side effects and minimize frequency of
administration by administration of gels. Moreover, overshooting the MIC levels in the brain, as
seen in case of i.v route is not likely to improve the treatment but rather could cause toxicity in
case

of

certain

drugs

with
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small

therapeutic

window.
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